WO2012122383A2 - Inhibiteurs de pi3 kinase et leurs utilisations - Google Patents

Inhibiteurs de pi3 kinase et leurs utilisations Download PDF

Info

Publication number
WO2012122383A2
WO2012122383A2 PCT/US2012/028293 US2012028293W WO2012122383A2 WO 2012122383 A2 WO2012122383 A2 WO 2012122383A2 US 2012028293 W US2012028293 W US 2012028293W WO 2012122383 A2 WO2012122383 A2 WO 2012122383A2
Authority
WO
WIPO (PCT)
Prior art keywords
ring
nhc
nitrogen
optionally substituted
oxygen
Prior art date
Application number
PCT/US2012/028293
Other languages
English (en)
Other versions
WO2012122383A3 (fr
Inventor
Lixin Qiao
Deqiang Niu
Russell C. Petter
Zhendong Zhu
Original Assignee
Avila Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avila Therapeutics, Inc. filed Critical Avila Therapeutics, Inc.
Priority to CN201280021536.0A priority Critical patent/CN103501610A/zh
Priority to CA2829558A priority patent/CA2829558A1/fr
Priority to JP2013557866A priority patent/JP2014511395A/ja
Priority to AU2012225382A priority patent/AU2012225382B2/en
Priority to EP12755552.2A priority patent/EP2683243A4/fr
Publication of WO2012122383A2 publication Critical patent/WO2012122383A2/fr
Publication of WO2012122383A3 publication Critical patent/WO2012122383A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to compounds useful as inhibitors of PI3 kinase.
  • the invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
  • PBKs Phosphatidylinositol 3-kinases
  • PI3K-related kinases phosphorylate lipid molecules, rather than proteins, and are consequently known as lipid kinases.
  • PBKs phosphorylate the 3'-OH position of the inositol ring of phosphatidyl inositides.
  • Class I PBKs are of particular interest and are further divided into Class IA and Class IB kinases based on sequence homology and substrate specificity.
  • Class IA PBKs contain a p85 regulatory subunit that heterodimerizes with a pi 10a, ⁇ ⁇ , or ⁇ ⁇ catalytic subunit. These kinases are commonly known as ⁇ , ⁇ , and ⁇ and are activated by receptor tyrosine kinases.
  • the Class IB PBK contains a ⁇ ⁇ catalytic subunit and is commonly known as ⁇ . ⁇ is activated by heterotrimeric G-proteins.
  • PBKa and ⁇ have a broad tissue distribution, while ⁇ and ⁇ are primarly expressed in leukocytes.
  • Class II and Class III PBKs are less well-known and well-studied than Class I PBKs.
  • Class II comprises three catalytic iso forms: C2a, C2p, and C2y.
  • C2a and C2p are expressed throughout the body, while C2y is limited to hepatocytes.
  • No regulatory subunit has been identified for the Class II PBKs.
  • Class III PBKs exist as heterodimers of i 50 regulatory subunits and Vps34 catalytic subunits, and are thought to be involved in protein trafficking.
  • PI4KA phophatidylinositol 4-kinases
  • PI4KIIIa phophatidylinositol 4-kinases
  • PBK-related kinases In addition to the classical PB kinases, there is a group of "PBK-related kinases,” sometimes known as Class IV PBKs.
  • Class IV PBKs contain a catalytic core similar to the PBKs and PMKs.
  • These members of the PBK superfamily are serine/threonine protein kinases and include ataxia telangiectasia mutated (ATM) kinase, ataxia telangiectasia and Rad3 related (ATR) kinase, DNA-dependent protein kinase (DNA-PK) and mammalian Target of Rapamycin (mTOR).
  • ATM telangiectasia mutated
  • ATR ataxia telangiectasia and Rad3 related
  • mTOR mammalian Target of Rapamycin
  • PBKs and related enzymes are associated with abnormal cellular responses triggered by such kinase-mediated events as those described above.
  • diseases include, but are not limited to, autoimmune diseases, inflammatory diseases, proliferative diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases. Accordingly, there remains a need to find inhibitors of PBKs and related enzymes useful as therapeutic agents.
  • Figure 1 depicts MS analysis confirming covalent modification of PBKa by 1-11.
  • the present invention provides irreversible inhibitors of one or more PB kinases and conjugates thereof.
  • such compounds include those of formula I:
  • Ring A, Ring B, Ring C, Ring D, T 1 , T 2 , and R are as defined and described herein.
  • aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
  • “carbocyclic” refers to a monocyclic C3-C8 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • bridged bicyclic refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge.
  • a "bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a "bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen).
  • a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:
  • lower alkyl refers to a Ci_ 4 straight or branched alkyl group.
  • exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
  • lower haloalkyl refers to a Ci_ 4 straight or branched alkyl group that is substituted with one or more halogen atoms.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), ⁇ (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • Ci_g (or Ci_ 6 ) saturated or unsaturated, straight or branched, hydrocarbon chain
  • bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
  • alkylene refers to a bivalent alkyl group.
  • An "alkylene chain” is a polymethylene group, i.e., -(CH 2 ) n -, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
  • a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • alkenylene refers to a bivalent alkenyl group.
  • a substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • cyclopropylenyl refers to a bivalent cyclopropyl group of the following structure:
  • aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • aryl may be used interchangeably with the term “aryl ring.”
  • aryl refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
  • aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
  • heteroaryl and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
  • heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quatemized form of a basic nitrogen.
  • Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
  • heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
  • Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin- 3(4H)-one.
  • heteroaryl group may be mono- or bicyclic.
  • heteroaryl may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted.
  • heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
  • heterocycle As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
  • nitrogen includes a substituted nitrogen.
  • the nitrogen may be N (as in 3,4- dihydro-2H-pyrrolyl), ⁇ (as in pyrrolidinyl), or + NR (as in N-substituted pyrrolidinyl).
  • a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
  • saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
  • heterocycle refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
  • compounds of the invention may contain "optionally substituted” moieties.
  • substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
  • an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • Suitable monovalent substituents on R° are independently halogen, -(CH 2 ) 0 2 R*, -(haloR*), -(CH 2 ) 0 2 OH, -(CH 2 ) 0 2 OR*, -(CH 2 ) 0 2 CH(OR*) 2 ; -O(haloR'), -CN, -N 3 , -(CH 2 ) 0 2 C(0)R*, -(CH 2 ) 0 2 C(0)OH, -(CH 2 ) 0 2 C(0)OR*, -(CH 2 ) 0 2 SR*, -(CH 2 )o 2 SH, -(CH 2 )o 2 NH 2 , -(CH 2 ) 0 2 NHR*, -(CH 2 ) 0 2 NR* 2 , -N0 2 , -SiR*
  • Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -0(CR 2 ) 2 3 0-, wherein each independent occurrence of R is selected from hydrogen, Ci_6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on the aliphatic group of R * include halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2 , or -N0 2 , wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci_ 4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0 iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R ⁇ , -NR ⁇ 2 , -C(0)R ⁇ , -C(0)OR ⁇ , -C(0)C(0)R ⁇ , -C(0)CH 2 C(0)R ⁇ , -S(0) 2 R ⁇ , -S(0) 2 NR ⁇ 2 , -C(S)NR ⁇ 2 , -C(NH)NR ⁇ 2 , or -N(R ⁇ )S(0) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, Ci_ 6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ⁇ , taken together with their intervening atom(s
  • Suitable substituents on the aliphatic group of R' are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2 , or
  • each R* is unsubstituted or where preceded by "halo” is substituted only with one or more halogens, and is independently Ci_ 4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0 iPh, or a 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N (Ci_ 4 alkyl) 4 salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
  • a warhead moiety, R 1 of a provided compound comprises one or more deuterium atoms.
  • the term "irreversible” or “irreversible inhibitor” refers to an inhibitor (i.e. a compound) that is able to be covalently bonded to a PI3 kinase in a substantially nonreversible manner. That is, whereas a reversible inhibitor is able to bind to (but is generally unable to form a covalent bond with) a PI3 kinase, and therefore can become dissociated from the a PI3 kinase an irreversible inhibitor will remain substantially bound to a PI3 kinase once covalent bond formation has occurred.
  • Methods for identifying if a compound is acting as an irreversible inhibitor are known to one of ordinary skill in the art. Such methods include, but are not limited to, enzyme kinetic analysis of the inhibition profile of the compound with PI3 kinase, the use of mass spectrometry of the protein drug target modified in the presence of the inhibitor compound, discontinuous exposure, also known as "washout," experiments, and the use of labeling, such as radiolabeled inhibitor, to show covalent modification of the enzyme, as well as other methods known to one of skill in the art.
  • warheads refers to a functional group present on a compound of the present invention wherein that functional group is capable of covalently binding to an amino acid residue (such as cysteine, lysine, histidine, or other residues capable of being covalently modified) present in the binding pocket of the target protein, thereby irreversibly inhibiting the protein.
  • an amino acid residue such as cysteine, lysine, histidine, or other residues capable of being covalently modified
  • an inhibitor is defined as a compound that binds to and /or inhibits PI3 kinase with measurable affinity.
  • an inhibitor has an IC 50 and/or binding constant of less about 50 ⁇ , less than about 1 ⁇ , less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
  • measurable affinity and “measurably inhibit,” as used herein, means a measurable change in a PI3 kinase activity between a sample comprising a compound of the present invention, or composition thereof, and a PI3 kinase, and an equivalent sample comprising a PI3 kinase, in the absence of said compound, or composition thereof.
  • the present invention provides a compound of formula I:
  • R 1 is a warhead group
  • Ring A is an optionally substituted ring selected from a 4-8 membered saturated or partially
  • unsaturated heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-15 membered saturated or partially unsaturated bridged or spiro bicyclic heterocyclic ring having at least one nitrogen, at least one oxygen, and optionally 1-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • T 1 is a covalent bond or a bivalent straight or branched, saturated or unsaturated Ci_ 6 hydrocarbon chain wherein one or more methylene units of T 1 are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, -OC(O)-, -C(0)0-, -C(0)N(R)-, -N(R)C(0)-, -N(R)C(0)N(R)-, -S0 2 -, -S0 2 N(R)-, -N(R)S0 2 -, or -N(R)S0 2 N(R)-;
  • Ring C is absent or an optionally substituted group selected from phenyl, a 3-7 membered
  • T 2 is a covalent bond or a bivalent straight or branched, saturated or unsaturated Ci_ 6 hydrocarbon chain wherein one or more methylene units of T 2 are optionally and independently replaced by -0-, -S-, -N(R)-, -C(O)-, -OC(O)-, -C(0)0-, -C(0)N(R)-, -N(R)C(0)-, -N(R)C(0)N(R)-, -S0 2 -, -S0 2 N(R)-, -N(R)S0 2 -, or -N(R)S0 2 N(R)-; and
  • Ring A is an optionally substituted 5-6 membered saturated or partially unsaturated heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is an optionally substituted 6- membered saturated or partially unsaturated heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A is optionally substituted morpholinyl. In certain embodiments, Ring A is unsubstituted morpholinyl. In some embodiments, Ring A is optionally substituted tetrahydropyranyl. In certain embodiments, Ring A is:
  • Ring A is an optionally substituted 5-15 membered saturated or partially unsaturated bridged bicyclic heterocyclic ring having at least one nitrogen, at least one oxygen, and optionally 1-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Ring A is an optionally substituted 5-10 membered saturated or partially unsaturated bridged bicyclic heterocyclic ring having at least one nitrogen, at least one oxygen, and optionally 1-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Ring A is a bridged, bicyclic morpholino group.
  • Ring A is an optionally substituted ring having the structure:
  • Ring A is of the formula:
  • v, j, p, and g are independently 1, 2, or 3.
  • Ring A is an optionally substituted bicyclic (fused or spiro- fused) ring selected from:
  • Ring B is an optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is an optionally substituted 8-10 membered bicyclic heteroaryl ring having 2 nitrogen atoms. In some embodiments, Ring B is lH-indazolyl, benzimidazolyl, or indolyl. In certain embodiments, Ring B is lH-indazolyl. In certain embodiments, Ring B is substituted or unsubstituted phenyl. In certain embodiments, Ring B is substituted phenyl. In certain embodiments, Ring B is phenol.
  • T 2 is a bivalent, straight, saturated Ci_ 6 hydrocarbon chain. In some embodiments, T 2 is a bivalent, straight, saturated Ci_ 3 hydrocarbon chain. In some embodiments, T 2 is -CH 2 - or -CH 2 CH 2 -. In certain embodiments, T 2 is -C(O)-. In certain embodiments, T 2 is -CH 2 -C(0)- or -C(0)-CH 2 -.
  • T 2 is -CH 2 -C(0)-, wherein it will be understood by one of ordinary skill in the art that the methylene group of - CH 2 -C(0)- is attached to Ring D and the carbon of the carbonyl group of -CH 2 -C(0)- is attached to Ring C.
  • T 2 is a covalent bond.
  • Ring D is an optionally substituted 6-membered saturated heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Ring D is a piperazinyl or piperidinyl ring.
  • Ring D is an optionally substituted 6-membered partially unsaturated heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Ring D is tetrahydropyridyl.
  • Ring D is optionally substituted phenyl.
  • Ring D is optionally substituted pyridyl.
  • Ring D is an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring. In certain embodiments, Ring D is cyclohexyl. In certain embodiments, Ring D is absent. In some embodiments, Ring D is a 7-12 membered saturated or partially unsaturated bridged bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring D is a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Ring D is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring D is an 9-membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring D is an optionally substituted ring selected from benzothiazole, benzoxazole, or benzimidazole.
  • R 1 group of formula I is a warhead group.
  • R 1 is -L-Y, wherein:
  • Y is hydrogen, Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 R e groups; and
  • Q is a covalent bond or a bivalent Ci_ 6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by -N(R)-, -S-, -0-, -C(O)-, -OC(O)-, -C(0)0-, -SO-, or -S0 2 -, -N(R)C(0)-, -C(0)N(R)-, -N(R)S0 2 -, or -S0 2 N(R)-; and
  • Z is hydrogen or Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN.
  • L is substituted with one or more R groups. In some embodiments, L is unsubstituted. In some embodiments, L is substituted with an optionally substituted Ci_ 6 aliphatic group. In some embodiments, L is substituted with optionally substituted phenyl. In some embodiments, L is substituted with an optionally substituted C3-6 cycloaliphatic group. In some embodiments, L is substituted with cyclopropyl. In some embodiments, L is substituted with phenyl. In some embodiments, L is substituted with -CF 3 .
  • L is a covalent bond
  • L is a bivalent Ci_8 hydrocarbon chain wherein at least one methylene unit of L is replaced by -C(O)-. In certain embodiments, L is a bivalent Ci_8 hydrocarbon chain wherein at least two methylene units of L are replaced by -C(O)-. In some embodiments, L is -C(0)CH 2 CH 2 C(0)-, -C(0)CH 2 NHC(0)-, -C(0)CH 2 NHC(0)CH 2 CH 2 C(0)-, or -C(0)CH 2 CH 2 CH 2 NHC(0)CH 2 CH 2 C(0)-.
  • L is a bivalent Ci_8 hydrocarbon chain wherein at least one methylene unit of L is replaced by -S(0) 2 -.
  • L is a bivalent Ci_8 hydrocarbon chain wherein at least one methylene unit of L is replaced by -S(0) 2 - and at least one methylene unit of L is replaced by -C(O)-.
  • L is a bivalent Ci_8 hydrocarbon chain wherein at least one methylene unit of L is replaced by -S(0) 2 - and at least two methylene units of L are replaced by -C(O)-.
  • L is - S(0) 2 CH 2 CH 2 NHC(0)CH 2 CH 2 C(0)- or -S(0) 2 CH 2 CH 2 NHC(0)-.
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two additional methylene units of L are optionally and independently replaced by -NRC(O)-, -C(0)NR-, -N(R)S0 2 -, -S0 2 N(R)-, -S-, -S(O)-, -S0 2 -, -OC(O)-, -C(0)0-, cyclopropylene, -0-, -N(R)-, or -C(O)-.
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -C(O)-, -NRC(O)-, -C(0)NR-, -N(R)S0 2 -, -S0 2 N(R)-, -S-, -S(O)-, -S0 2 -, -OC(O)-, or -C(0)0-, and one or two additional methylene units of L are optionally and independently replaced by cyclopropylene, -0-, -N(R)-, or -C(O)-.
  • L is a bivalent C 2 _g straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -C(O)-, and one or two additional methylene units of L are optionally and independently replaced by cyclopropylene, -0-, -N(R)-, or -C(O)-.
  • L is a bivalent C 2 _ 8 straight or branched, hydrocarbon chain wherein L has at least one double bond.
  • a double bond may exist within the hydrocarbon chain backbone or may be "exo" to the backbone chain and thus forming an alkylidene group.
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain wherein L has at least one alkylidenyl double bond.
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -C(O)-.
  • L is a bivalent C 2 _g straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -OC(O)-.
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -NRC(O)-, -C(0)NR-, -N(R)S0 2 -, -S0 2 N(R)-, -S-, -S(O)-, -S0 2 -, -OC(O)-, or -C(0)0-, and one or two additional methylene units of L are optionally and independently replaced by cyclopropylene, -0-, -N(R)-, or -C(O)-.
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain wherein L has at least one triple bond.
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and at least one methylene unit of L is replaced by -N(R)-, -N(R)C(0)-, -C(O)-, -C(0)0-, or -OC(O)-, or - 0-.
  • Exemplary L groups include -C ⁇ C-, -C ⁇ CCH 2 N(isopropyl)-, -NHC(0)C ⁇ CCH 2 CH 2 -,
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one or two additional methylene units of L are independently replaced by -C(O)-, -NRC(O)-, -C(0)NR-, -N(R)S0 2 -, or -S0 2 N(R)-.
  • Exemplary L groups include -NHC(0)-cyclopropylene-S0 2 - and -NHC(O)- cyclopropylene-.
  • Y is hydrogen
  • Y is Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN.
  • Y is C 2 _ 6 alkenyl optionally substituted with oxo, halogen, N0 2 , or CN.
  • Y is C 2 _ 6 alkynyl optionally substituted with oxo, halogen, N0 2 , or CN.
  • Y is C 2 _ 6 alkenyl.
  • Y is C 2 _ 4 alkynyl.
  • Y is a saturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Y is substituted with 1 -4 R e groups, wherein each R e is as defined above and described herein.
  • Y is a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 R e groups, wherein each R e is as defined above and described herein.
  • exemplary such rings are epoxide and oxetane rings, wherein each ring is substituted with 1-2 R e groups, wherein each R e is as defined above and described herein.
  • Y is a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
  • Such rings include piperidine and pyrrolidine, wherein each ring is substituted with 1-4 R e groups, wherein each R e is as defined
  • Y is , , or , wherein each R, Q, Z, and R e is as defined above and described herein.
  • Y is piperazine.
  • Y is a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
  • Y is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein each ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein..
  • Y is L — * , wherein R e is as defined above and described herein. In certain embodiments, Y is cyclopropyl optionally substituted with halogen, CN or N0 2 .
  • Y is a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
  • Y is a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
  • Y is cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl wherein each ring is substituted with 1-4 e groups, wherein each R e is as defined
  • each R e is as defined above and described herein.
  • Y is a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
  • Y is selected from:
  • each R and R e is as defined above and described herein.
  • Y is a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 R e groups, wherein each R e group is as defined above and described herein.
  • Y is phenyl, pyridyl, or pyrimidinyl, wherein each ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
  • Y is selected from:
  • each R e is as defined above and described herein.
  • Y is a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 R e groups, wherein each R e group is as defined above and described herein.
  • Y is a 5 membered partially unsaturated or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 1- 4 R e groups, wherein each R e group is as defined above and described herein.
  • rings are isoxazolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, thienyl, triazole, thiadiazole, and oxadiazole, wherein each ring is substituted with 1-3 R e groups, wherein each R e group is as defined above and described herein.
  • Y is selected from:
  • each R and R e is as defined above and described herein.
  • Y is an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein.
  • Y is a 9-10 membered bicyclic, partially unsaturated, or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein.
  • Exemplary such bicyclic rings include 2,3-dihydrobenzo[d]isothiazole, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein.
  • each R e group is independently selected from -Q-Z, oxo, N0 2 , halogen, CN, a suitable leaving group, or Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN, wherein Q is a covalent bond or a bivalent Ci_ 6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by -N(R)-, -S-, -0-, -C(O)-, -OC(O)-, -C(0)0-, -SO-, or -S0 2 -, - N(R)C(0)-, -C(0)N(R)-, -N(R)S0 2 -, or -S0 2 N(R)-; and Z is hydrogen or Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2
  • R e is Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN. In other embodiments, R e is oxo, N0 2 , halogen, or CN.
  • R e is -Q-Z, wherein Q is a covalent bond and Z is hydrogen (i.e., R e is hydrogen).
  • R e is -Q-Z, wherein Q is a bivalent Ci_ 6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by -NR-, -NRC(O)-, -C(0)NR-, -S-, -0-, -C(O)-, -SO-, or -S0 2 -.
  • R e is a suitable leaving group, ie a group that is subject to nucleophilic displacement.
  • a "suitable leaving” is a chemical group that is readily displaced by a desired incoming chemical moiety such as the thiol moiety of a cysteine of interest. Suitable leaving groups are well known in the art, e.g., see, “Advanced Organic Chemistry,” Jerry March, 5 th Ed., pp. 351-357, John Wiley and Sons, N.Y.
  • Such leaving groups include, but are not limited to, halogen, alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, acyloxy, and diazonium moieties.
  • suitable leaving groups include chloro, iodo, bromo, fluoro, acetoxy, methanesulfonyloxy (mesyloxy), tosyloxy, triflyloxy, nitro-phenylsulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy).
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain optionally substituted with one or more -R groups, wherein L has at least one double bond and at least one methylene unit of L is replaced by -C(O)-, -NRC(O)-, -C(0)NR-, -N(R)S0 2 -, -S0 2 N(R)-, -S-, -S(O)-, -S0 2 -, -OC(O)-, or -C(0)0-, and one or two additional methylene units of L are optionally and independently replaced by cyclopropylene, -0-, -N(R)-, or -C(O)-; and
  • Y is hydrogen or Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN; or
  • L is a bivalent C 2 _g straight or branched, hydrocarbon chain optionally substituted with one or more -R groups, wherein L has at least one double bond and at least one methylene unit of L is replaced by -C(O)-; and Y is hydrogen or Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN; or
  • (k) L is a bivalent C 2 _8 straight or branched, hydrocarbon chain optionally substituted with one or more -R groups, wherein one methylene unit of L is replaced by cyclopropylene and one or two additional methylene units of L are independently replaced by -NRC(O)-, -C(0)NR-, -N(R)S0 2 -, -S0 2 N(R)-, -S-, -S(O)-, -S0 2 -, -OC(O)-, or -C(0)0-; and Y is hydrogen or Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN; or is a covalent bond and Y is selected from:
  • R e is as defined above and described herein; or
  • each R and R e is as defined above and described herein;
  • each R and R e is as defined above and described herein;
  • R e is as defined above and described herein; or wherein each R, Q, Z, and R e is as defined above and described herein; or
  • R e groups wherein each R e is as defined above and described herein;
  • (vz ' z ' z) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein; or
  • (xz) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein; or
  • each R and R e is as defined above and described herein;
  • each R e is as defined above and described herein;
  • each R and R e is as defined above and described herein;
  • (n) L is -N(R)C(0)- and Y is selected from: ( ⁇ ' ) Ci_6 alkyl substituted with oxo, halogen, N0 2 , or CN; or
  • R e is as defined above and described herein; or
  • R e is as defined above and described herein; or wherein each R, Q, Z, and R e is as defined above and described herein; or
  • R e groups wherein each R e is as defined above and described herein;
  • (vz ' z ' z) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein; or
  • (xz) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein; or
  • each R and R e is as defined above and described herein;
  • each R e is as defined above and described herein;
  • each R and R e is as defined above and described herein;
  • R e is as defined above and described herein; or
  • R e is as defined above and described herein; or wherein each R, Q, Z, and R e is as defined above and described herein; or
  • each R and R e is as defined above and described herein;
  • each R e is as defined above and described herein;
  • each R and R e is as defined above and described herein;
  • (p_) L is a covalent bond, -CH 2 -, -NH-, -C(O)-, -CH 2 NH-, -NHCH 2 -, -NHC(O)-, -NHC(0)CH 2 OC(0)-, -CH 2 NHC(0)-, -NHS0 2 -, -NHS0 2 CH 2 -, -NHC(0)CH 2 OC(0)-, or -S0 2 NH-; and Y is selected from:
  • R e is as defined above and described herein; or
  • R e is as defined above and described herein; or wherein each R, Q, Z, and R e is as defined above and described herein; or
  • each R and R e is as defined above and described herein;
  • each R e is as defined above and described herein;
  • each R and R e is as defined above and described herein;
  • L is a bivalent C 2 _8 straight or branched, hydrocarbon chain optionally substituted with one or more -R groups, wherein two or three methylene units of L are optionally and independently replaced by -NRC(O)-, -C(0)NR-, -N(R)S0 2 -, -S0 2 N(R)-, -S-, -S(O)-, -S0 2 -, -OC(O)-, -C(0)0-, cyclopropylene, -0-, -N(R)-, or -C(O)- ; and Y is hydrogen or Ci_6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN.
  • the Y group of formula I is selected from those set forth in Table 1, below, wherein each wavy line indicates the point of attachment to the rest of the molecule.
  • each R e is independently a suitable leaving group, N0 2 , CN, or oxo.
  • each R e is independently a suitable leaving group, N0 2 , CN, or oxo.
  • R 1 is selected from:
  • R 1 is selected from:
  • a compound of formula I is of formula I-a, I-b, or I-c:
  • Ring A, Ring B, Ring C, Ring D, T 1 , and T 2 are as defined above and described in classes and subclasses herein, and R 2 is cyclopropyl or phenyl.
  • R 2 is cyclopropyl. In some embodiments, R 2 is phenyl.
  • a provided compound of formula I-d has one or more, more than one, or all of the features selected from:
  • Ring B is optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-2 nitrogen atoms, optionally substituted phenyl, or an optionally substituted 5-6 membered heteroaryl ring having 1-2 nitrogen atoms;
  • T 1 is a covalent bond
  • Ring C is a 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 nitrogen atoms;
  • T 2 is -C(O)- or -CH 2 C(0)-;
  • Ring D is optionally substituted phenyl.
  • Ring A is optionally substituted morpholinyl
  • T 1 is a covalent bond
  • Ring C is piperazinyl, piperdinyl, or tetrahydropyridyl; e) T 2 is -CH 2 C(0)-;
  • Ring D is phenyl
  • a provided compound of formula I-d has one or more, more than one, or all of the features selected from:
  • Ring A is optionally substituted morpholinyl
  • Ring B is aminopyrimidinyl
  • T 1 is a covalent bond
  • Ring C is piperazinyl
  • T 2 is -CH 2 C(0)-;
  • Ring D is phenyl
  • Ring A, Ring B, Ring C, and R 2 are as defined above and described in classes and subclasses herein.
  • Ring A, Ring B, Ring C, and R 2 are as defined above and described in classes and subclasses herein
  • a compound of formula I is of formula I-e:
  • Ring A, Ring B, Ring D, and R 1 are as defined above and described in classes and subclasses herein.
  • a provided compound of formula I-e has one or more, more than one, or all of the features selected from:
  • Ring A is optionally substituted morpholinyl
  • Ring B is optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-2 nitrogen atoms, optionally substituted phenyl, or an optionally substituted 5-6 membered heteroaryl ring having 1-2 nitrogen atoms;
  • Ring D is an optionally substituted group selected from phenyl or 6-membered heteroaryl ring having 1-3 nitrogens;
  • R 1 is -L-Y, wherein L is a bivalent C 2 _8 straight or branched, hydrocarbon chain optionally substituted with one or more -R groups, wherein L has at least one double bond and one or two additional methylene units of L are optionally and independently replaced by -NRC(O)-, - C(0)NR-, -N(R)S0 2 -, -S0 2 N(R)-, -S-, -S(O)-, -S0 2 -, -OC(O)-, -C(0)0-, cyclopropylene, -0-, - N(R)-, or -C(O)- ; and Y is hydrogen or Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN.
  • Ring D is phenyl
  • Ring B is aminopyrimidinyl
  • Ring D of a compound of formula I-e is phenyl to give a compound of formula I-e-/:
  • R 1 is -L-Y, wherein L is a bivalent C 2 _8 straight or branched, hydrocarbon chain optionally substituted with one or more -R groups, wherein L has at least one double bond and one or two additional methylene units of L are optionally and independently replaced by -NRC(O)-, - C(0)NR-, -N(R)S0 2 -, -S0 2 N(R)-, -S-, -S(O)-, -S0 2 -, -OC(O)-, -C(0)0-, cyclopropylene, -0-, - N(R)-, or -C(O)- ; and Y is hydrogen or Ci_ 6 aliphatic optionally substituted with oxo, halogen, N0 2 , or CN.
  • a provided compound of formula I-f has one or more, more than one, or all of the features selected from:
  • Ring B is aminopyrimidinyl
  • Ring A, Ring B, Ring C, and R 1 are as defined above and described in classes and subclasses herein, R 3 is -R, -C(0)R, or -S0 2 R, R 1 is attached to any substitutable atom on the benzothiazole (of a compound of formula I-f-i), benzoxazole (of a compound of formula I-f-w), or benzimidazole (of a compound of formula I-f- ⁇ ) ring, and the benzothiazole (of a compound of formula l-f-i), benzoxazole (of a compound of formula I-f-w), or benzimidazole (of a compound of formula ⁇ - ⁇ -iii) ring is optionally substituted.
  • R 3 is -R. In certain embodiments, R 3 is Ci_ 6 alkyl. In certain embodiments, R 3 is methyl or ethyl. In certain embodiments, R 3 is -C(0)R. In certain embodiments, R 3 is acetyl. In certain embodiments, R 3 is -S0 2 R.
  • a compound of formula l-f-i is of formula l-f-i-a:
  • Ring A, Ring B, Ring C, and R 1 are as defined above and described in classes and subclasses herein.
  • Ring A, Ring B, R 1 , and R 3 are as defined above and described in classes and subclasses herein.
  • the present invention provides any compound selected from those depicted in Table 3, above, or a pharmaceutically acceptable salt thereof.
  • provided compounds of formula I are generally prepared according to Scheme 1.
  • Ring B and Ring C are as defined above, M is a boronic acid or stannyl group, and R is a precursor to R 1 .
  • M is a boronic acid or stannyl group
  • R is a precursor to R 1 .
  • a first Suzuki/Stille/N-arylation affords compound sch-la, and a second Suzuki/Stille/N-arylation affords compound sch-lb.
  • R 1P group is then converted to a warhead group R ⁇ o give compound sch-lc.
  • the present invention provides irreversible inhibitors of one or more PI3 kinases.
  • Such compounds comprising a warhead group, designated as R 1 include those of formula I as described herein.
  • R 1 groups i.e. warhead groups
  • warhead groups are particularly suitable for covalently binding to a key cysteine residue in the binding domain of a PI3 kinase.
  • PI3 kinases, and mutants thereof include, but not limited to Glu542, Glu545 and Hisl047 (Samuels et al., Science (2004) 304: 552)
  • proximity of a warhead group to the cysteine of interest facilitates covalent modification of that cysteine by the warhead group.
  • Cysteine residues of PI3 kinase family members targeted for covalent modification by irreversible inhibitors of the present invention include those summarized in Table 4, below, where the "Target” refers to the protein of interest; the “Sequence Code” refers to the residue numbering protocol in accordance with the ExPASy proteomics server of the Swiss Institute of Bioinformatics (www.expasy.org); the "Sequence” refers to an identifying portion of the Target's amino acid sequence which includes the cysteine of interest; and the "Residue #” refers to the cysteine residue number as set forth in the sequence code.
  • cysteine residues of interest can also be described by an identifying portion of the Target's amino acid sequence which includes the cysteine of interest.
  • one or more of the following characteristics apply:
  • Cys838 of PI3K-alpha is characterized in that Cys838 is the cysteine embedded in the amino acid sequence LPYGCLS (SEQ ID NO: 3) of PI3K-alpha;
  • Cys869 of PI3K-gamma is characterized in that Cys869 is the cysteine embedded in the amino acid sequence LPYGCIS (SEQ ID NO: 4) of PI3K-gamma;
  • Cys815 of PI3K-delta is characterized in that Cys815 is the cysteine embedded in the amino acid sequence TPYGCLP (SEQ ID NO: 5) of PI3K-delta;
  • Cys841 of PBK-beta, Class 1A is characterized in that Cys841 is the cysteine embedded in the amino acid sequence LPYGCLA (SEQ ID NO: 6) of PBK-beta, Class 1A;
  • Cysl l l9 of PBK-beta, Class 2 is characterized in that Cysl l l9 is the cysteine embedded in the amino acid sequence VIFRCFS (SEQ ID NO: 7) of PBK-beta, Class 2;
  • Cys3683 of DNA-PK is characterized in that Cys3683 is the cysteine embedded in the amino acid sequence NKDSKPPGNL KECSPWMSDF (SEQ ID NO: 8) of DNA-PK; Cys2770 of ATM-Kinase is characterized in that Cys2770 is the cysteine embedded in the amino acid sequence SQRSGVLEWCTGTVPIGEFL (SEQ ID NO: 9) of ATM-kinase; Cys2753 of ATM-Kinase is characterized in that Cys2770 is the cysteine embedded in the amino acid sequence RNTETRKRKLTICTYKVVPL (SEQ ID NO: 10) of ATM- kinase;
  • Cys 1840 of PI4KA is characterized in that Cys 1840 is the cysteine embedded in the amino acid sequence TAPGCGVIECIPDCTSRDQL (SEQ ID NO: 11) of PI4KA;
  • Cys 1844 of PI4KA is characterized in that Cys 1844 is the cysteine embedded in the amino acid sequence TAPGCGVIECIPDCTSRDQL (SEQ ID NO: 12) of PI4KA; and/or Cys 1797 of PI4KA is characterized in that Cys 1797 is the cysteine embedded in the amino acid sequence GQKISWQAAIFKVGDDCRQD (SEQ ID NO: 13) of PI4KA.
  • cysteine residues are conserved across PB kinase family members. Such cysteine residues are designated by Cys Group, as set forth in Table 4-a, below. Thus, for the purposes of clarity, the grouping of conserved cysteine residues is exemplified by Table 4-a, below. Table 4-a.
  • compounds of the present invention include a warhead group characterized in that provided compounds covalently modify the Cys862 residue of PB-kinase alpha, thereby irreversibly inhibiting PB kinase-alpha.
  • compounds of the present invention include a warhead group characterized in that provided compounds covalently modify one or more of Cys862 of PBK- alpha, Cys2243 of MTOR, Cys838 of PBK-alpha, Cys869 of PBK-gamma, Cys815 of PBK- delta, Cys841 of PBK-beta, Class 1A, Cysl 119 of PBK-beta, Class 2, Cys3683 of DNA-PK, Cys2770 of ATM-Kinase, Cys2753 of ATM-Kinase, Cysl840 of PI4KA, Cysl844 of PI4KA, or Cysl 797 of PI4KA.
  • Cys869 of PBK gamma corresponds to Cys838 of PBK alpha, Cys815 of PBK delta, Cys841 of PBK beta, Classl and Cysl 119 of PBK beta, Class2.
  • compounds of the present invention include a warhead group characterized in that provided compounds target each of Cys869 of PBK gamma, Cys838 of PBK alpha, Cys815 of PBK delta, Cys841 of PBK beta, Classl and Cysl 119 of PBK beta, Class2, thereby irreversibly inhibit each of these kinases.
  • the R 1 warhead group is characterized in that the -L-Y moiety, as defined and described below, is capable of covalently binding to a cysteine residue thereby irreversibly inhibiting the enzyme.
  • the cysteine residue is the Cys862 residue of PB kinase alpha.
  • the cysteine residue is any of Cys862 of PBK-alpha, Cys2243 of MTOR, Cys838 of PBK-alpha, Cys869 of PBK-gamma, Cys815 of PBK-delta, Cys841 of PBK-beta, Class 1A, Cysl 119 of PBK-beta, Class 2, Cys3683 of DNA-PK, Cys2770 of ATM-Kinase, Cys2753 of ATM-Kinase, Cysl840 of PI4KA, Cysl844 of PI4KA, or Cysl797 of PI4KA.
  • the cysteine residue is any of Cys869 of PI3K gamma, Cys838 of PI3K alpha, Cys815 of PI3K delta, Cys841 of PI3K beta, Classl or Cysl 119 of PI3K beta, Class2.
  • R 1 groups include, but are not limited to, those described herein and depicted in Table 2, infra.
  • the present invention provides a conjugate comprising one or more PI3 kinases having a cysteine residue, CysX, wherein the CysX is covalently, and irreversibly, bonded to an inhibitor, such that inhibition of the PI3 kinase is maintained, wherein CysX is selected from Cys862 of PI3K-alpha, Cys2243 of MTOR, Cys838 of PI3K-alpha, Cys869 of PI3K-gamma, Cys815 of PI3K-delta, Cys841 of PBK-beta, Class 1A, Cysl 119 of PBK-beta, Class 2, Cys3683 of DNA-PK, Cys2770 of ATM-Kinase, Cys2753 of ATM-Kinase, Cysl 840 of PI4KA, Cysl 844 of PI4KA, or Cysl 797 of PI4KA.
  • CysX is selected from Cys862 of
  • the present invention provides a conjugate of the formula C:
  • CysX is selected from Cys862 of PBK-alpha, Cys2243 of MTOR, Cys838 of PBK-alpha, Cys869 of PBK-gamma, Cys815 of PBK-delta, Cys841 of PBK-beta, Class 1A, Cysl 119 of PBK-beta, Class 2, Cys3683 of DNA-PK, Cys2770 of ATM-Kinase, Cys2753 of ATM- Kinase, Cysl 840 of PI4KA, Cysl 844 of PI4KA, or Cysl 797 of PI4KA;
  • the modifier is a bivalent group resulting from covalent bonding of a warhead group with the
  • the warhead group is a functional group capable of covalently binding to CysX;
  • the inhibitor moiety is a moiety that binds in the active site of the PI3 kinase.
  • the present invention provides a conjugate comprising PBK- alpha having a cysteine residue, Cys862, wherein the Cys862 is covalently, and irreversibly, bonded to an inhibitor, such that inhibition of the PBK-alpha is maintained.
  • the present invention provides a conjugate of the formula C-l: Cys862-modifier-inhibitor moiety
  • Cys862 is Cys862 of PBK-alpha
  • the modifier is a bivalent group resulting from covalent bonding of a warhead group with the
  • the warhead group is a functional group capable of covalently binding to Cys862;
  • the inhibitor moiety is a moiety that binds in the active site of the PBK-alpha.
  • the present invention provides a comjugate comprising a PB kinase having a cysteine residue, wherein the cysteine is a conserved cysteine that is Cys869 of PI3K gamma, Cys838 of PBK alpha, Cys815 of PBK delta, Cys841 of PI3K beta, Classl or Cysl l l9 of PBK beta, Class2.
  • the present invention provides a conjugate of the formula C-2:
  • CysX 1 is any one or more of Cys869 of PBK gamma, Cys838 of PBK alpha, Cys815 of PBK delta, Cys841 of PBK beta, Class 1 or Cysl 119 of PBK beta, Class 2;
  • the modifier is a bivalent group resulting from covalent bonding of a warhead group with the CysX 1 of the PB kinase;
  • the warhead group is a functional group capable of covalently binding to CysX 1 ;
  • the inhibitor moiety is a moiety that binds in the active site of the PB kinase.
  • the inhibitor moiety of any of conjugates C, C-1, or C-2 is of formula I*:
  • the inhibitor moiety of any of conjugates C, C-1, or C-2 is of formula I*-e, -e-i, P-f, P-f-i, P-f- «, or I*-f-i «:
  • the present invention provides a conjugate of formula C-I:
  • Cys862 is as described herein and each of the Modifier, Ring A, Ring B, Ring C, Ring D, T 1 , and T 2 groups of the conjugate is as defined for formulae C-1 and I above and described in classes and subclasses herein.
  • the present invention provides a conjugate of any of formulae C-I-d, C- -e, and C-I-e-i, C-I-f, C-I-f-i, C-I-f-M, and C-I-f- ⁇ :
  • Cys862 is as described herein and each of the Modifier, Ring A, Ring B, Ring C, Ring D, T 1 , T 2 , R 2 , and R 3 groups of the conjugate is as defined for formula C-l, I, I-e, I-e-i, I-f, l-f-i, I-f- ⁇ , and I-f- ⁇ and described in classes and subclasses herein.
  • the modifier moiety of any of conjugate C, C-l, C-2, C-I, C- I-d, C-I-e, and C-I-e-/, C-I-f, C-I-f-/, C-I-f- «, and C-I-f-m is selected from those set forth in Table 5, below.
  • Exemplary modifiers further include any bivalent group resulting from covalent bonding of a warhead moiety found in Table 1 or Table 2 with a cysteine of PI3 kinase. It will be understood that the exemplary modifiers below are shown as conjugated to the sulfliydryl of CysX.
  • compositions are provided.
  • the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • the amount of compound in compositions of this invention is such that is effective to measurably inhibit a PI3 kinase, or a mutant thereof (for example, Glu542, Glu545 and His 1047), in a biological sample or in a patient.
  • the amount of compound in compositions of this invention is such that is effective to measurably inhibit a PI3 kinase, or a mutant thereof, in a biological sample or in a patient.
  • a composition of this invention is formulated for administration to a patient in need of such composition.
  • a composition of this invention is formulated for oral administration to a patient.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention refers to a nontoxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropy
  • a "pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • the term "inhibitorily active metabolite or residue thereof means that a metabolite or residue thereof is also an inhibitor of a PI3 kinase, or a mutant thereof (for example, Glu542, Glu545 and Hisl047).
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non- toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • a non- toxic parenterally acceptable diluent or solvent for example as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.
  • compositions of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration.
  • provided compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
  • Compounds and compositions described herein are generally useful for the inhibition of kinase activity of one or more enzymes.
  • Examples of kinases that are inhibited by the compounds and compositions described herein and against which the methods described herein are useful include ⁇ , ⁇ , ⁇ , ⁇ Class 1 ⁇ ( ⁇ ), ⁇ Class 2 (PI3KC2P), mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof.
  • the activity of a compound utilized in this invention as an inhibitor of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof may be assayed in vitro, in vivo or in a cell line.
  • In vitro assays include assays that determine inhibition of either the phosphorylation activity and/or the subsequent functional consequences, or ATPase activity of activated ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2p, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof.
  • Alternate in vitro assays quantitate the ability of the inhibitor to bind to ⁇ , ⁇ , ⁇ , ⁇ , PI3 C2p, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa.
  • Inhibitor binding may be measured by radiolabeling the inhibitor prior to binding, isolating the inhibitor/PBKa, inhibitor/ ⁇ , inhibitor/ ⁇ , inhibitor/ ⁇ , inhibitor/PI3KC2p, inhibitor/mTOR, inhibitor/DNA-PK, inhibitor/ATM kinase or inhibitor/PI4KIIIa complex and determining the amount of radiolabel bound.
  • inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with ⁇ , ⁇ , ⁇ , ⁇ , PI3 C2p, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa bound to known radioligands.
  • Detailed conditions for assaying a compound utilized in this invention as an inhibitor of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof, are set forth in the Examples below.
  • a provided compound comprising a warhead moiety is more effective at inhibiting a PB kinase, or a mutant thereof, as compared to a corresponding compound wherein the R 1 moiety of formula I, I-a, I-b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, I-f-/, I-f-//, l-f-iii, l-f-i-a, l-f-ii-a, or l-f-iii-a is instead a non-warhead group or is completely absent (i.e., is hydrogen).
  • a compound of formula I, I-a, I-b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, I-f-/, I-f-//, l-f-iii, l-f-i-a, l-f-ii-a, or l-f-iii-a can be more effective at inhibition of PB kinase, or a mutant thereof (for example, Glu542, Glu545 and His 1047), as compared to a corresponding compound wherein the R 1 moiety of formula I, I-a, I-b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, I-f-/, I-f-/,
  • a provided compound comprising a warhead moiety can be more potent with respect to an IC 50 against a PB kinase, or a mutant thereof (for example, Glu542, Glu545 and His 1047), than a corresponding compound wherein the R 1 moiety of formula I, I-a, I-b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, I-f-/, I-f-//, I-f-//, l-f-iii, l-f-i-a, l-f-ii-a, or I-f- iii-a is instead a non-warhead moiety or is absent.
  • a compound of formula I, I-a, I-b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, I-f-/, I-f-//, l-f-iii, l-f-i-a, l-f-ii-a, or ⁇ -i-iii-a is measurably more potent, wherein such potency is observed after about 1 minute, about 2 minutes, about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 8 hours, about 12 hours, about 16 hours, about 24 hours, or about 48 hours, than a corresponding compound of formula I, I-a, I- b, I-c, I-d, I-d-/, ⁇ - ⁇ -i-a, I-e, I-e-
  • a compound of formula I, I-a, I-b, I-c, I-d, I-d-/, ⁇ - ⁇ -i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, I-f-/, I-f-//, l-f-iii, l-f-i-a, l-f-ii-a, or l-f-iii-a is any of about 1.5 times, about 2 times, about 5 times, about 10 times, about 20 times, about 25 times, about 50 times, about 100 times, or even about 1000 times more potent than a corresponding compound of formula I, I-a, I-b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, I-f-/, I-f-/////
  • the phosphatidylinositol 3 -kinase pathway is a central signaling pathway that exerts its effect on numerous cellular functions including cell cycle progression, proliferation, motility, metabolism and survival (Marone, et al. Biochim. Biophys. Acta (2008) 1784: 159-185).
  • Activation of receptor tyrosine kinases in the case of Class IA PBKs, or G-proteins in the case of Class IB ⁇ causes phosphorylation of phosphatidylinositol-(4,5)-diphosphate, resulting in membrane-bound phosphatidylinositol-(3,4,5)-triphosphate.
  • the latter promotes the transfer of a variety of protein kinases from the cytoplasm to the plasma membrane by binding of phosphatidylinositol-(3,4,5)-triphosphate to the pleckstrin-homology (PH) domain of the kinase.
  • PH pleckstrin-homology
  • PI3K phosphotidylinositide-dependent kinase 1
  • Akt also known as Protein Kinase B or PKB
  • Phosphorylation of such kinases then allows for the activation or deactivation of numerous other pathways, involving mediators such as GSK3, mTOR, PRAS40, FKHD, NF- ⁇ , BAD, Caspase-9, and others. These pathways are involved in many cellular processes, such as cell cycle progression, cell survival and apoptosis, cell growth, transcription, translation, metabolism, degranulation, and cell motility.
  • PTEN a phosphatase that catalyzes the dephosphorylation of phosphatidylinositol-(3,4,5)-triphosphate to phosphatidylinositol-(4,5)-diphosphate.
  • PTEN is mutated into an inactive form, permitting a constitutive activation of the PI3K pathway.
  • a targeting of PI3K itself or individual downstream kinases in the PI3K pathway provide a promising approach to mitigate or even abolish the disregulation in many cancers and thus restore normal cell function and behavior.
  • PI3Ks PI3 Kinases
  • PI3CA Mutations of the PIK3CA gene that codes for PI3Ka are observed in over 30% of solid tumors.
  • the PIK3CA is also amplified in many cancers. Expression of a constitutively active PI3Ka form allows cell survival and migration under suboptimal conditions, leading to tumor formation and metastasis.
  • the overexpression of PI3Ka and/or mutations in PI3Ka have been implicated in a whole host of cancers including, but not limited to, ovarian, cervical, lung, colorectal, gastric, brain, breast and hepatocellular carcinomas.
  • ⁇ 3 ⁇ has also been implicated in carcinogenesis.
  • the loss of ⁇ 3 ⁇ impedes cell growth of mouse embryonic fibroblasts (Jia, et ah, Nature (2008) 454: 776-779).
  • the role of ⁇ 3 ⁇ in tumorigenesis caused by PTEN loss was investigated in prostatic epithelium. Ablation of ⁇ 3 ⁇ in the prostate blocked the tumorigenesis driven by PTEN loss in the anterior prostate. ⁇ 3 ⁇ is an important target for treating solid tumors.
  • upstream signalling pathways examples include over-expression of the receptor tyrosine kinase Erb2 in a variety of tumors leading to activation of PI3K-mediated pathways (Harari, et al, Oncogene (2000) 19: 6102-6114) and over-expression of the oncogene Ras (Kauffmann-Zeh, et al, Nature (1997) 385: 544-548).
  • Class IA PI3Ks may contribute indirectly to tumorigenesis caused by various downstream signaling events.
  • loss of the effect of the PTEN tumor-suppressor phosphatase that catalyzes conversion of phosphatidylinositide-(3,4,5)-triphosphate back to phosphatidylinositide-(4,5)-diphosphate is associated with a very broad range of tumors via deregulation of PI3K-mediated production of phosphatidylinositide-(3,4,5)-triphosphate (Simpson and Parsons, Exp. Cell Res. (2001) 264: 29- 41).
  • Akt Noncholson and Anderson, Cellular Signalling (2002) 381-395.
  • Class IA PI3K enzymes will also contribute to tumorigenesis via its function in tumor-associated stromal cells.
  • PI3K signaling is known to play an important role in mediating angiogenic events in endothelial cells in response to pro-angiogenic factors such as VEGF (Abid, et al, Arterioscler. Thromb. Vase. Biol. (2004) 24: 294-300).
  • VEGF vascular endothelial cells
  • VEGF vascular endothelial growth factor
  • PI3K inhibitors should provide therapeutic benefit via inhibition of tumor cell invasion and metastasis.
  • Class I PI3K enzymes play an important role in the regulation of immune cells with PI3K activity contributing to pro-tumorigenic effects of inflammatory cells (Coussens and Werb, Nature (2002) 420: 860-867). These findings suggest that pharmacological inhibitors of Class I PI3K enzymes should be of therapeutic value for treatment of the various forms of the disease of cancer comprising solid tumors such as carcinomas and sarcomas and the leukemias and lymphoid malignancies.
  • inhibitors of Class I PI3K enzymes should be of therapeutic value for treatment of, for example, cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate, and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, esophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukemias (including ALL and CML), multiple myeloma and lymphomas.
  • cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, esophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of le
  • PI3K has been linked to the control of cell and organ size.
  • Overexpression of PBKa leads to an enlarged heart in the mouse (Shioi et al, EMBO J. (2000) 19: 2537-2548).
  • An even bigger increase in heart size is seen when Akt/PKB, which is downstream of PI3K, is overexpressed.
  • This phenomenon can be reversed by treatment with rapamycin, an inhibitor of mTOR, signifying that Akt/PKB signaling is effected via mTOR to control heart size.
  • mice deficient in ⁇ show no effect on heart size.
  • ⁇ has been shown to influence contractility of the heart.
  • TAC transverse aortic constriction
  • mice deficient in ⁇ displayed fibrosis and chamber dilation leading to acute heart failure.
  • ⁇ and ⁇ have also been shown to regulate infarct size after ischemia/reperfusion injury (Doukas et al., Proc. Natl. Acad. Sci. USA (2006) 103: 19866-19871).
  • treatment of animals with TG100-115, a ⁇ / ⁇ dual inhibitor has been shown to decrease inflammatory responses and edema formation, and is currently being investigated in clinical trials for acute myocardial infarction.
  • ⁇ and ⁇ are primarily expressed in leukocytes. Although ⁇ and ⁇ have been implicated in chronic inflammation and allergy through knockout studies, PBKa and ⁇ cannot be studied in knockout mice, because mice lacking PBKa and ⁇ die during embryonic development. ⁇ knockout mice display impaired migration of cells important for the inflammatory response, such as neutrophils, macrophages, mast cells, dendritic cells and granulocytes. Mast cells are primary effectors in allergic responses, asthma and atopic dermatitis due to the expression of the high affinity receptor for IgE on their surface. In addition, ⁇ knockout mice are protected against systemic anaphylaxis. ⁇ inactive mice also display an impaired IgE-mediated inflammatory response, and their mast cells display defective migration.
  • Inflammatory diseases in which ⁇ and ⁇ have been implicated include, but are not limited to, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, acute pancreatitis, psoriasis, and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Class II PBKs are characterized by a C-terminal C2 homology domain. Class II comprises three catalytic isoforms: C2a, C2p, and C2y. C2a and C2p are expressed throughout the body, while C2y is limited to hepatocytes. No regulatory subunit has been identified for the Class II PBKs.
  • Various stimuli have been reported to activate class II PBKs, including chemokines (MCP-1), cytokines (leptin and TNFa), LP A, insulin and EGF-, PDGF-, and SCF- receptors. It has been suggested that PI3KC2P may be involved in LPA-induced migration of ovarian and cervical cancer cells (Maffucci, et ah, J. Cell. Biol. (2005) 169: 789-799).
  • PI4Ks phophatidylinositol 4-kinases
  • PI4KA also known as PI4KIIIa
  • PI4KIIIa is the mostly closely related to PBKs.
  • PI4KIIIa is expressed primarily in the nervous system, and is mainly localized to the endoplasmic reticulum, nucleus and plasma membrane. At the plasma membrane, PI4KIIIa associates with ion channels which are involved in cytoskeletal remodeling and membrane blebbing (Kim, et al., EMBO J. (2001) 20: 6347-6358).
  • mTOR Mammalian target of rapamycin
  • mTOR is a serine/threonine protein kinase that is regulated by growth factors and nutrient availability. mTOR is responsible for coordinating protein synthesis, cell growth and proliferation. Much of the knowledge of mTOR signaling is based on studies with its ligand rapamycin. Rapamycin first binds to the 12 kDa immunophilin FK506-binding protein (FKBP 12) and this complex inhibits mTOR signaling (Tee and Blenis, Seminars in Cell and Developmental Biology. 2005, 16, 29-37).
  • FKBP 12 immunophilin FK506-binding protein
  • mTOR protein consists of a catalytic kinase domain, an FKBP12-Rapamycin binding (FRB) domain, a putative repressor domain near the C-terminus and up to 20 tandemly-repeated HEAT motifs at the N-terminus, as well as FRAP-ATM-TRRAP (FAT) and FAT C-terminus domain (Huang and Houghton, Curr. Opin. in Pharmacology (2003) 3: 371-377).
  • mTOR kinase is a key regulator of cell growth and has been shown to regulate a wide range of cellular functions including translation, transcription, mRNA turnover, protein stability, actin cytoskeleton reorganization and autophagy (Jacinto and Hall, Nat. Rev.
  • mTOR kinase integrates signals from growth factors (such as insulin or insulin-like growth factor) and nutrients (such as amino acids and glucose) to regulate cell growth.
  • mTOR kinase is activated by growth factors through the PDK- Akt pathway.
  • the most well characterized function of mTOR kinase in mammalian cells is regulation of translation through two pathways, namely activation of ribosomal S6K1 to enhance translation of mRNAs that bear a 5 '-terminal oligopyrimidine tract (TOP) and suppression of 4E- BP1 to allow CAP-dependent mRNA translation.
  • TOP 5 '-terminal oligopyrimidine tract
  • Endothelial cell proliferation is stimulated by vascular endothelial cell growth factor (VEGF) activation of the PI3K-Akt-mTOR signalling pathway (Dancey, Expert Opinion on Investigational Drugs, 2005, 14, 313-328).
  • VEGF vascular endothelial cell growth factor
  • mTOR kinase signaling is believed to partially control VEGF synthesis through effects on the expression of hypoxia-inducible factor-la (HIF-la) (Hudson, et al, Mol. Cell. Biol. (2002) 22: 7004-7014).
  • tumor angiogenesis may depend on mTOR kinase signaling in two ways, through hypoxia-induced synthesis of VEGF by tumour and stromal cells, and through VEGF stimulation of endothelial proliferation and survival through PI3K-Akt-mTOR signalling.
  • mTOR kinase should be of therapeutic value for treatment of the various forms of the disease of cancer comprising solid tumours such as carcinomas and sarcomas and the leukemias and lymphoid malignancies.
  • solid tumours such as carcinomas and sarcomas
  • leukemias and lymphoid malignancies In addition to tumorigenesis, there is evidence that mTOR kinase plays a role in an array of hamartoma syndromes.
  • the tumor suppressor proteins such as TSC1, TSC2, PTEN and LKB1 tightly control mTOR kinase signaling.
  • rapamycin analog everolimus
  • cardiac allograft vasculopathy Eisen, et ah, New Engl. J. Med. (2003) 349: 847-858.
  • Elevated mTOR kinase activity has been associated with cardiac hypertrophy, which is of clinical importance as a major risk factor for heart failure and is a consequence of increased cellular size of cardiomyocytes (Tee and Blenis, Seminars in Cell and Developmental Biology, 2005, 29-37).
  • mTOR kinase inhibitors are expected to be of value in the prevention and treatment of a wide variety of diseases in addition to cancer.
  • Dual inhibition of mTOR and PI3K has been shown to be particularly effective in shutting down cell proliferation that could be responsible in various cancers.
  • a dual inhibitor of mTOR and PI3Ka known as PI- 103 was shown to be more effective in blocking proliferation in glioma cells (Fan, et ah, Cell Cycle (2006) 5: 2301-2305).
  • a combination therapy of rapamycin, which is an mTOR inhibitor, and PIK90, a pure PI3Ka inhibitor were used.
  • NVP- BEZ235 Another dual mTOR-PI3K inhibitor is an imidazo[4,5-c]quinoline known as NVP- BEZ235 (Maira, et al, Mol. Cancer Ther. (2008) 7: 1851-1863). NVP-BEZ235 showed efficacy in reduced tumor size in PC3M-tumor bearing mice and achieved tumor stasis in a glioblastoma model. In addition, NVP-BEZ235 given in combination with the standard of care temozolomide caused tumor regression in a glioblastoma model without a significant effect on body weight gain, showing that a dual mTOR-PI3Ka inhibitor can enhance efficacy of other anticancer agents when given in combination. NVP-BEZ235 is currently in clinical trials for cancer treatment.
  • DNA-PK The DNA-dependent protein kinase
  • DNA-PKcs a large catalytic subunit
  • Ku a regulatory component
  • DNA DSBs are regarded as the most lethal lesion a cell can encounter.
  • eukaryotic cells have evolved several mechanisms to mediate their repair. In higher eukaryotes, the predominant of these mechanisms is DNA nonhomologous end-joining (NHEJ), also known as illegitimate recombination.
  • NHEJ DNA nonhomologous end-joining
  • DNA-PK plays a key role in this pathway. Increased DNA-PK activity has been demonstrated both in vitro and in vivo and correlates with the resistance of tumour cells to IR and bifunctional alkylating agents (Muller, et al, Blood (1998) 92: 2213-2219; Sirzen, et al, Eur. J.
  • DNA-PK activity has been proposed as a cellular and tumor resistance mechanism.
  • inhibition of DNA-PK with a small molecule inhibitor may prove efficacious in tumors where over-expression is regarded as a resistance mechanism.
  • DNA-PK inhibitors may also prove useful in the treatment of retroviral mediated diseases. For example it has been demonstrated that loss of DNA-PK activity severely represses the process of retroviral integration (Daniel, et al, Science (1999) 284: 644-7).
  • the ATM gene encodes a 370-kDa protein that belongs to the PI3K superfamily which phosphorylates proteins rather than lipids.
  • the 350 amino acid kinase domain at the C- terminus of this protein is the only segment of ATM with an assigned function.
  • Exposure of cells to ionizing radiation (IR) triggers ATM kinase activity and this function is required for arrests in Gl, S, and G2 phases of the cell cycle (Shiloh and Kastan, Adv. Cancer Res. (2001) 83: 209- 254).
  • pan-PBK inhibitors Agents that target two or more PI3Ks are called pan-PBK inhibitors.
  • provided compounds inhibit one or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2p, mTOR, DNA-PK, ATM kinase, PMKIIIa and/or another member of the PBK superfamily.
  • provided compounds inhibit two or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase, PMKIIIa and/or another member of the PBK superfamily, or a mutant thereof (for example, Glu542, Glu545 and His 1047), and are therefore pan-PBK inhibitors.
  • a pan-PBK inhibitor inhibits two or more of ⁇ , ⁇ , ⁇ , and ⁇ . In certain embodiments, a pan-PBK inhibitor inhibits three or more of ⁇ , ⁇ , ⁇ , and ⁇ . In certain embodiments, a pan-PBK inhibitor inhibits ⁇ , ⁇ , ⁇ , and ⁇ .
  • Wortmannin is a natural product that is a pan-PBK inhibitor. In addition to the classical PBKs, wortmannin also inhibits DNA-PK, mTOR, ATR, ATM, PI4K and polo-like kinase (PLK). While wortmannin itself is too toxic to use therapeutically, modified versions of wortmannin have been discovered that show decreased toxicity as compared to wortmannin.
  • PX-866 which attenuated growth of a tumor xenograft in mice at around 10 mg/kg (Ihle, et al, Mol. Cancer Ther. (2004) 3: 763-772).
  • IC87114 a selective inhibitor of ⁇ , has shown effects on neutrophil migration (Sadhu, et al, J. Immunol. (2003) 170: 2647-2654) and TNF la-stimulated elastase exocytosis from neutrophils in an inflammation model (Sadhu, et al, Biochem. Biophys. Res. Commun. (2003) 308: 764-769). IC87114 has also been shown to inhibit acute myeloid leukemia cell proliferation and survival (Billottet, et al, Oncogene (2006) 25: 6648-6659).
  • TGX-221 is a selective inhibitor of ⁇ , and is an analog of the pan-PBK inhibitor LY294002 (Jackson, et al, Nat. Med. (2005) 11 : 507-514). TGX-221 has been shown to interfere with stress-induced phosphatidylinositol-3,4-diphosphate production and integrin ⁇ 3 ⁇ 4 ⁇ 3 -mediated adhesion in platelets. These results suggest that TGX-221 or other inhibitors of ⁇ could have an anti-thrombotic effect in vivo.
  • PI- 103 is a pan-PBK inhibitor and displays dual inhibition PBK/mTOR.
  • PI- 103 has been shown to attenuate proliferation of glioma, breast, ovarian and cervical tumor cells in mouse xenograft models (Raynaud, et al, Cancer Res. (2007) 67: 5840-5850).
  • AS-252424, AS-604850 and AS-605240 are selective ⁇ inhibitors that have been used to block neutrophil chemotaxis. These compounds have been shown to minimize progression of joint destruction in a rheumatoid arthritis model (Camps, et al, Nat. Med. (2005) 11 : 936-943).
  • ZSTK474 is a PBK inhibitor that was selected for its ability to block tumor growth.
  • ZSTK474 displayed a strong anti-tumoral activity in a mouse xenograft model (Yaguchi, et al., J. Natl. Cancer Inst. (2006) 98: 545-556).
  • XL765 and XL147 quinoxaline compounds that are dual PBK/mTOR inhibitors, have shown efficacy in xenograft models both as single agents as well as in combination with standard chemotherapy. Both compounds are currently in clinical trials for treatment of solid tumors.
  • SF1126 is a pan-PBK inhibitor which has entered clinical trials to target cell growth, proliferation and angiogenesis. SF1126 has demonstrated promising in vivo activity in a variety of mouse cancer models, including prostate, breast, ovarian, lung, multiple myeloma, brain and other cancers.
  • Neurofibromatosis type I is a dominantly inherited human disease affecting one in 2500-3500 individuals.
  • organ systems are affected, including bones, skin, iris, and the central nervous system, as manifested in learning disabilities and gliomas.
  • a hallmark of NF1 is the development of benign tumors of the peripheral nervous system (neurofibromas), which vary greatly in both number and size among patients.
  • Neurofibromas are heterogeneous tumors composed of Schwann cells, neurons, fibroblasts and other cells, with Schwann cells being the major (60-80%) cell type.
  • PBK has been implicated in NF1 (Yang, et al. J. Clin. Invest. 116: 2880 (2006).
  • Schwannomas are peripheral nerve tumors comprised almost entirely of Schwann- like cells, and typically have mutations in the neurofibromatosis type II (NF2) tumor suppressor gene.
  • NF2 neurofibromatosis type II
  • NF2 neurofibromatosis type II
  • NF2 neurofibromatosis type II
  • NF2 neurofibromatosis type II
  • NF2 neurofibromatosis type II
  • NF2 neurofibromatosis type II
  • NF2 neurofibromatosis type II
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment may be administered after one or more symptoms have developed.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • Provided compounds are inhibitors of one of more of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PMKIIIa and are therefore useful for treating one or more disorders associated with activity of one or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PMKIIIa.
  • the present invention provides a method for treating a PBKa -mediated, a ⁇ -mediated, a ⁇ -mediated, a ⁇ -mediated, a PI3KC2P-mediated, an mTOR-mediated, a DNA-PK-mediated, an ATM-mediated and/or a PI4KIIIa-mediated disorder comprising the step of administering to a patient in need thereof a compound of the present invention, or pharmaceutically acceptable composition thereof.
  • PBKa-mediated means any disease or other deleterious condition in which one or more of ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PMKIIIa, or a mutant thereof, are known to play a role.
  • another embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which one or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PMKIIIa, or a mutant thereof, are known to play a role.
  • a provided compound is selective for PBKa as compared to other PI3 kinases.
  • a provided compound is 10-fold, 20-fold, 50-fold, 100-fold, or 1000-fold selective for PBKa vs. one or more other PB kinases (e.g., ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa).
  • the present invention provides a method for treating one or more disorders, diseases, and/or conditions wherein the disorder, disease, or condition is a cancer, a neurodegenative disorder, an angiogenic disorder, a viral disease, an autoimmune disease, an inflammatory disorder, a hormone-related disease, conditions associated with organ transplantation, immunodeficiency disorders, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), liver disease, pathologic immune conditions involving T cell activation, a cardiovascular disorder, or a CNS disorder.
  • the disorder, disease, or condition is a cancer, a neurodegenative disorder, an angiogenic disorder, a viral disease, an autoimmune disease, an inflammatory disorder, a hormone-related disease, conditions associated with organ transplantation, immunodeficiency disorders, a destructive bone disorder, a proliferative disorder
  • Diseases and conditions treatable according to the methods of this invention include, but are not limited to, cancer, neurofibromatosis, ocular angiogenesis, stroke, diabetes, hepatomegaly, cardiovascular disease, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders, inflammation, neurological disorders, angiogenic disorders, a hormone-related disease, conditions associated with organ transplantation, immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), liver disease, pathologic immune conditions involving T cell activation, and CNS disorders in a patient.
  • a human patient is treated with a compound of the current invention and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein said compound of is present in an amount to measurably
  • Compounds of the current invention are useful in the treatment of a proliferative disease selected from a benign or malignant tumor, carcinoma of the brain, kidney (e.g., renal cell carcinoma (RCC)), liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, endometrium, cervix, testis, genitourinary tract, esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastomas, neuroblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma or a tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, adenoma, adenocarcinoma, keratoacant
  • the present invention provides a method for treating or lessening the severity of neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), Schwann cell neoplasms (e.g. malignant peripheral nerve sheath tumors (MPNST's)), or Schwannomas.
  • NF1 neurofibromatosis type I
  • NF2 neurofibromatosis type II
  • MPNST's malignant peripheral nerve sheath tumors
  • Compounds according to the invention are useful in the treatment of inflammatory or obstructive airways diseases, resulting, for example, in reduction of tissue damage, airways inflammation, bronchial hyperreactivity, remodeling or disease progression.
  • Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection.
  • Treatment of asthma is also to be understood as embracing treatment of subjects, e.g. of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "whez infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics.
  • Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, such as therapy for or intended to restrict or abort symptomatic attack when it occurs, for example antiinflammatory or bronchodilatory.
  • Prophylactic benefit in asthma may in particular be apparent in subjects prone to "morning dipping". "Morning dipping" is a recognized asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.
  • Compounds of the current invention can be used for other inflammatory or obstructive airways diseases and conditions to which the present invention is applicable and include acute lung injury (ALI), adult/acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy.
  • the invention is also applicable to the treatment of bronchitis of whatever type or genesis including, but not limited to, acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • aluminosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • aluminosis anthracosis
  • asbestosis chalicosis
  • ptilosis ptilosis
  • siderosis silicosis
  • tabacosis tabacosis and byssinosis.
  • compounds of the invention are also useful in the treatment of eosinophil related disorders, e.g. eosinophilia, in particular eosinophil related disorders of the airways (e.g.
  • eosinophilic infiltration of pulmonary tissues including hypereosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil- related disorders of the airways consequential or concomitant to Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.
  • Compounds of the invention are also useful in the treatment of inflammatory or allergic conditions of the skin, for example psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, and other inflammatory or allergic conditions of the skin.
  • Compounds of the invention may also be used for the treatment of other diseases or conditions, such as diseases or conditions having an inflammatory component, for example, treatment of diseases and conditions of the eye such as conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, and inflammatory disease in which autoimmune reactions are implicated or having an autoimmune component or etiology, including autoimmune hematological disorders (e.g.
  • hemolytic anemia aplastic anemia, pure red cell anemia and idiopathic thrombocytopenia
  • systemic lupus erythematosus rheumatoid arthritis, polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven- Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g.
  • ulcerative colitis and Crohn's disease endocrine opthalmopathy
  • Grave's disease sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minal change nephropathy).
  • Neurodegenerative disease which can be treated according to the methods of this invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity and hypoxia.
  • Angiogenesis refers to the growth of new blood vessels, and is an important contributor to a number of pathological conditions. For example, the role of angiogenesis in promoting and supporting the growth and viability of solid tumors is well documented. Angiogenesis also contributes to other pathological conditions, such as psoriasis and asthma, and pathological conditons of the eye, such as the wet form of age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, and retinopathy of prematurity.
  • PI3K proteins are pro- angiogenic (Graupera et al.
  • the subject compounds provide advantages for inhibiting angiogenesis, for example, to treat eye disease associated with ocular angiogenesis, such as by topical administration of the subject compounds.
  • Compounds according to the invention can be formulated for topical administration.
  • the irreversible inhibitor can be formulated for topical delivery to the lung (e.g., as an aerosol, such as a dry powder or liquid formulation) to treat asthma, as a cream, ointment, lotion or the like for topical application to the skin to treat psoriasis, or as an ocular formulation for topical application to the eye to treat an ocular disease.
  • Such a formulation will contain a subject inhibitor and a pharmaceutically acceptable carrier.
  • the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of cancer, an autoimmune disorder, a proliferative disorder, an inflammatory disorder, a neurodegenerative or neurological disorder, an angiogenic disorder, schizophrenia, a bone-related disorder, liver disease, or a cardiac disorder.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • Compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dose unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • a compound of formula I, I-a, I-b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, I-e-i-a, I-e-i-b, I-f, I-f-/, I-f-//, I-f-//, I-f-/-«, l-f-ii-a, or l-i-iii-a can provide prolonged duration of action when administered to a patient as compared to a corresponding compound of formula I, I-a, I-b, I-c, I-d, I-d-/, I-d-/- «, I-e, I-e-/, I-e-/- «, I-e-i-b, I-f, I-f-/, I-f-//, I-f-///, I-f-/-fl, I-f-ii-a, or ⁇ -i-ii-
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle.
  • injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide- polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol
  • the dosage form may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • embedding compositions examples include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the invention relates to a method of inhibiting protein kinase activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
  • the invention relates to a method of inhibiting ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PMKIIIa, or a mutant thereof (for example, Glu542, Glu545 and His 1047), activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
  • the invention relates to a method of irreversibly inhibiting ⁇ , ⁇ , ⁇ , ⁇ , ⁇ 2 ⁇ , mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof, activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Inhibition of protein kinase, or a protein kinase selected from ⁇ , ⁇ , ⁇ , ⁇ , PI3 C2p, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof, activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ- transplantation, biological specimen storage, and biological assays.
  • Another embodiment of the present invention relates to a method of inhibiting protein kinase activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.
  • the invention relates to a method of inhibiting one or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3 C2p, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof (for example, Glu542, Glu545 and His 1047), activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.
  • the invention relates to a method of irreversibly inhibiting one or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PMKIIIa, or a mutant thereof (for example, Glu542, Glu545 and His 1047), activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.
  • the present invention provides a method for treating a disorder mediated by one or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof (for example, Glu542, Glu545 and His 1047), in a patient in need thereof, comprising the step of administering to said patient a compound according to the present invention or pharmaceutically acceptable composition thereof.
  • a disorder mediated by one or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3KC2P, mTOR, DNA-PK, ATM kinase and/or PI4KIIIa, or a mutant thereof (for example, Glu542, Glu545 and His 1047), in a patient in need thereof, comprising the step of administering to said patient a compound according to the present invention or pharmaceutically acceptable composition thereof.
  • a disorder mediated by one or more of ⁇ , ⁇ , ⁇ , ⁇ , PI3
  • additional therapeutic agents that are normally administered to treat that condition may also be present in the compositions of this invention.
  • additional therapeutic agents that are normally administered to treat a particular disease, or condition are known as "appropriate for the disease, or condition, being treated.”
  • a compound of the current invention may also be used to advantage in combination with other antiproliferative compounds.
  • antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitor
  • aromatase inhibitor as used herein relates to a compound which inhibits estrogen production, for instance, the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively.
  • the term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole.
  • Exemestane is marketed under the trade name AromasinTM.
  • Formestane is marketed under the trade name LentaronTM.
  • Fadrozole is marketed under the trade name AfemaTM.
  • Anastrozole is marketed under the trade name ArimidexTM.
  • Letrozole is marketed under the trade names FemaraTM or FemarTM.
  • Aminoglutethimide is marketed under the trade name OrimetenTM.
  • a combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, such as breast tumors.
  • antiestrogen as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level.
  • the term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride.
  • Tamoxifen is marketed under the trade name NolvadexTM.
  • Raloxifene hydrochloride is marketed under the trade name EvistaTM.
  • Fulvestrant can be administered under the trade name FaslodexTM.
  • a combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, such as breast tumors.
  • anti-androgen as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CasodexTM).
  • gonadorelin agonist as used herein includes, but is not limited to abarelix, goserelin and goserelin acetate. Goserelin can be administered under the trade name ZoladexTM.
  • topoisomerase I inhibitor includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148.
  • Irinotecan can be administered, e.g. in the form as it is marketed, e.g. under the trademark CamptosarTM.
  • Topotecan is marketed under the trade name Hy camp tinTM.
  • topoisomerase II inhibitor includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, such as CaelyxTM), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide.
  • Etoposide is marketed under the trade name EtopophosTM.
  • Teniposide is marketed under the trade name VM 26-Bristol
  • Doxorubicin is marketed under the trade name AcriblastinTM or AdriamycinTM.
  • Epirubicin is marketed under the trade name FarmorubicinTM.
  • Idarubicin is marketed, under the trade name ZavedosTM.
  • Mitoxantrone is marketed under the trade name Novantron.
  • microtubule active agent relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate, vinflunine, and vinorelbine; discodermolides; cochicine and epothilones and derivatives thereof.
  • Paclitaxel is marketed under the trade name TaxolTM and Abraxane®.
  • Docetaxel is marketed under the trade name TaxotereTM.
  • Vinblastine sulfate is marketed under the trade name Vinblastin R.PTM.
  • Vincristine sulfate is marketed under the trade name FarmistinTM.
  • alkylating agent includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name CyclostinTM. Ifosfamide is marketed under the trade name HoloxanTM.
  • histone deacetylase inhibitors or "HDAC inhibitors” relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
  • SAHA suberoylanilide hydroxamic acid
  • antimetabolite includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed.
  • Capecitabine is marketed under the trade name XelodaTM.
  • Gemcitabine is marketed under the trade name GemzarTM.
  • platinum compound as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin.
  • Carboplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark CarboplatTM.
  • Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark EloxatinTM.
  • the term "compounds targeting/decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti-angiogenic compounds” as used herein includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101, SU6668 and GFB-111; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (PDGFR),
  • BCR-Abl kinase and mutants, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib or nilotinib (AMN107); PD 180970; AG957; NSC 680410; PD 173955 from ParkeDavis; or dasatinib (BMS-354825); j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK1, PKB/Akt, and Ras/MAPK family members, and/or members of the cyclin-dependent kinase family (CDK) including staurosporine derivatives, such as midostaurin; examples of further compounds include UCN-01, safmgol, BAY 43-9006,
  • Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition e.g. thalidomide (ThalomidTM) and TNP-470.
  • ThilomidTM thalidomide
  • TNP-470 TNP-470.
  • Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. inhibitors of phosphatase 1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof.
  • Compounds which induce cell differentiation processes include, but are not limited to, retinoic acid, ⁇ - ⁇ - or ⁇ - tocopherol or a- ⁇ - or ⁇ -tocotrienol.
  • cyclooxygenase inhibitor as used herein includes, but is not limited to, Cox- 2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CelebrexTM), rofecoxib (VioxxTM), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
  • Cox- 2 inhibitors such as celecoxib (CelebrexTM), rofecoxib (VioxxTM), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
  • bisphosphonates includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.
  • Etridonic acid is marketed under the trade name DidronelTM.
  • Clodronic acid is marketed under the trade name BonefosTM.
  • Tiludronic acid is marketed under the trade name SkelidTM.
  • Pamidronic acid is marketed under the trade name ArediaTM.
  • Alendronic acid is marketed under the trade name FosamaxTM.
  • Ibandronic acid is marketed under the trade name BondranatTM.
  • Risedronic acid is marketed under the trade name ActonelTM.
  • Zoledronic acid is marketed under the trade name ZometaTM.
  • mTOR inhibitors relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (Rapamune®), everolimus (CerticanTM), CCI-779 and ABT578.
  • heparanase inhibitor refers to compounds which target, decrease or inhibit heparin sulfate degradation.
  • the term includes, but is not limited to, PI-88.
  • biological response modifier refers to a lymphokine or interferons.
  • inhibitor of Ras oncogenic isoforms such as H-Ras, K-Ras, or N-Ras, as used herein refers to compounds which target, decrease or inhibit the oncogenic activity of Ras; for example, a “farnesyl transferase inhibitor” such as L-744832, DK8G557 or Rl 15777 (ZarnestraTM).
  • telomerase inhibitor refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, such as telomestatin.
  • methionine ammopeptidase inhibitor refers to compounds which target, decrease or inhibit the activity of methionine ammopeptidase.
  • Compounds which target, decrease or inhibit the activity of methionine ammopeptidase include, but are not limited to, bengamide or a derivative thereof.
  • proteasome inhibitor refers to compounds which target, decrease or inhibit the activity of the proteasome.
  • Compounds which target, decrease or inhibit the activity of the proteasome include, but are not limited to, Bortezomib (VelcadeTM) and MLN 341.
  • MMP matrix metalloproteinase inhibitor
  • the term “matrix metalloproteinase inhibitor” or (“MMP” inhibitor) as used herein includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g.
  • FMS-like tyrosine kinase inhibitors which are compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, ⁇ - ⁇ -D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, which are compounds which target, decrease or inhibit anaplastic lymphoma kinase.
  • FMS-like tyrosine kinase receptors are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.
  • HSP90 inhibitors includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteosome pathway.
  • Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, such as 17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors.
  • antiproliferative antibodies includes, but is not limited to, trastuzumab (HerceptinTM), Trastuzumab-DMl, erbitux, bevacizumab (AvastinTM), rituximab (Rituxan ® ), PR064553 (anti-CD40) and 2C4 Antibody.
  • trastuzumab HerceptinTM
  • Trastuzumab-DMl erbitux
  • bevacizumab AvastinTM
  • rituximab Rasteran ®
  • PR064553 anti-CD40
  • compounds of the current invention can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML.
  • compounds of the current invention can be administered in combination with, for example, farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP- 16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
  • HDAC histone deacetylase
  • SAHA suberoylanilide hydroxamic acid
  • HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065 including, but not limited to, N-hydroxy-3-[4-[[[2-(2-methyl-lH-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof and N- hydroxy-3-[4-[(2-hydroxyethyl) ⁇ 2-(lH-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide, or a pharmaceutically acceptable salt thereof, especially the lactate salt.
  • Somatostatin receptor antagonists as used herein refer to compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230.
  • Tumor cell damaging approaches refer to approaches such as ionizing radiation.
  • the term "ionizing radiation” referred to above and hereinafter means ionizing radiation that occurs as either electromagnetic rays (such as X- rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et al, Eds., 4 th Edition, Vol. 1 , pp. 248-275 (1993).
  • EDG binders and ribonucleotide reductase inhibitors.
  • EDG binders refers to a class of immunosuppressants that modulates lymphocyte recirculation, such as FTY720.
  • ribonucleotide reductase inhibitors refers to pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and/or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and/or pentostatin.
  • Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-lH-isoindole-l ,3-dione derivatives.
  • VEGF vascular endothelial growth factor
  • l-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof l-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate
  • AngiostatinTM EndostatinTM
  • anthranilic acid amides ZD4190; ZD6474; SU5416; SU6668
  • bevacizumab or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab
  • VEGF aptamer such as Macugon
  • FLT-4 inhibitors, FLT-3 inhibitors VEGFR-2 IgGI antibody
  • Angiozyme RI 4610)
  • Bevacizumab AvastinTM
  • Photodynamic therapy refers to therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers.
  • Examples of photodynamic therapy include treatment with compounds, such as VisudyneTM and porfimer sodium.
  • Angiostatic steroids refers to compounds which block or inhibit angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, 11-a-epihydrocotisol, cortexolone, 17a-hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.
  • angiogenesis such as, e.g., anecortave, triamcinolone, hydrocortisone, 11-a-epihydrocotisol, cortexolone, 17a-hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.
  • Implants containing corticosteroids refers to compounds, such as fiuocinolone and dexamethasone.
  • chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action.
  • the compounds of the invention are also useful as co-therapeutic compounds for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs.
  • a compound of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
  • the invention includes a combination of a compound of the invention as hereinbefore described with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said compound of the invention and said drug substance being in the same or different pharmaceutical composition.
  • Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate; non-steroidal glucocorticoid receptor agonists; LTB4 antagonists such LY293111, CGS025019C, CP-195543, SC-53228, BIIL 284, ONO 4057, SB 209247; LTD4 antagonists such as montelukast and zafMukast; PDE4 inhibitors such cilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden), V-l 1294A (Napp), BAY 19-8004 (Bayer), SCH- 351591 (Schering- Plough), Arofylline (Almirall Prodesfarma), PD 189659 / PD 168787 (Parke-
  • Suitable bronchodilatory drugs include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate.
  • Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine.
  • chemokine receptors e.g. CCR-1 , CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10
  • CXCR1 , CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists such as Schering-Plough antagonists SC-351125, SCH- 55700 and SCH-D
  • Takeda antagonists such as N-[[4-[[[[6,7-dihydro-2-(4-methylphenyl)- 5H-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H- pyran-4- aminium chloride (TAK-770).
  • a compound of the current invention may also be used in combination with known therapeutic processes, for example, the administration of hormones or radiation.
  • a provided compound is used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
  • a compound of the current invention can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds.
  • a compound of the current invention can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.
  • Those additional agents may be administered separately from an inventive compound-containing composition, as part of a multiple dosage regimen.
  • those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.
  • the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention.
  • a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
  • the present invention provides a single unit dosage form comprising a compound of the current invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of an inventive can be administered.
  • compositions which comprise an additional therapeutic agent that additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 100 mg/kg body weight/day of the additional therapeutic agent can be administered.
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the compounds of this invention, or pharmaceutical compositions thereof, may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters.
  • an implantable medical device such as prostheses, artificial valves, vascular grafts, stents and catheters.
  • Vascular stents for example, have been used to overcome restenosis (re -narrowing of the vessel wall after injury).
  • patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor.
  • Implantable devices coated with a compound of this invention are another embodiment of the present invention.
  • a compound of the present invention may be tethered to a detectable moiety to form a probe compound.
  • a probe compound of the invention comprises an irreversible kinase inhibitor of formula I, I-a, I-b, I-c, I-d, I-d-i, l-d-i-a, I-e, I-e-i, l-e-i-a, l-e-i-b, I-f, l-f-i, l-f-ii, l-f-iii, l-f-i-a, l-f-ii-a, or l-f-iii-a, as described herein, a detectable moiety, and a tethering moiety that attaches the inhibitor to the detectable moiety.
  • such probe compounds of the present invention comprise a provided compound of formula I, I-a, I-b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, I- f-i, l-f-ii, l-f-ii, l-f-i-a, l-f-ii-a, or l-f-iii-a tethered to a detectable moiety, R p , by a bivalent tethering moiety, -T p -.
  • the tethering moiety may be attached to a compound of formula I, I-a, I- b, I-c, I-d, I-d-/, l-d-i-a, I-e, I-e-/, l-e-i-a, l-e-i-b, I-f, l-f-i, l-f-ii, l-f-ii-a, l-f-ii-a, or I-f- iii-a via any substitutable carbon or nitrogen on the molecule or via R 1 .
  • R 1 is a bivalent warhead group denoted as R 1 .
  • a provided probe compound is of formula II:
  • Ring A, Ring B, T 1 , Ring C, T 2 , and Ring D are as defined above with respect to formula I, and described in classes and subclasses herein, R 1 is a bivalent warhead group, T p is a bivalent tethering moiety; and R p is a detectable moiety.
  • a provided probe compound is of formula Il-e, Il-f, II-f-i, -f-M, or II-f- ⁇ :
  • Ring A, Ring B, Ring C, T 2 , Ring D, and R 3 are as defined above with respect to formula I-e, I-f, l-f-i, l-f-ii, and l-f-iii, respectively, and described in classes and subclasses herein, R 1 is a bivalent warhead group, T p is a bivalent tethering moiety; and R p is a detectable moiety.
  • R p is a detectable moiety selected from a primary label or a secondary label.
  • R p is a detectable moiety selected from a fluorescent label (e.g., a fluorescent dye or a fluorophore), a mass-tag, a chemiluminescent group, a chromophore, an electron dense group, or an energy transfer agent.
  • a fluorescent label e.g., a fluorescent dye or a fluorophore
  • mass-tag e.g., a chemiluminescent group, a chromophore, an electron dense group, or an energy transfer agent.
  • detectable moiety is used interchangeably with the term “label” and “reporter” and relates to any moiety capable of being detected, e.g., primary labels and secondary labels.
  • a presence of a detectable moiety can be measured using methods for quantifying (in absolute, approximate or relative terms) the detectable moiety in a system under study.
  • such methods are well known to one of ordinary skill in the art and include any methods that quantify a reporter moiety (e.g., a label, a dye, a photocrosslinker, a cytotoxic compound, a drug, an affinity label, a photoaffinity label, a reactive compound, an antibody or antibody fragment, a biomaterial, a nanoparticle, a spin label, a fluorophore, a metal- containing moiety, a radioactive moiety, quantum dot(s), a novel functional group, a group that covalently or noncovalently interacts with other molecules, a photocaged moiety, an actinic radiation excitable moiety, a ligand, a photoisomerizable moiety, biotin, a biotin analog (e.g., biotin sulfoxide), a moiety incorporating a heavy atom, a chemically cleavable group, a photocleavable group, a redox-active agent, an a reporter mo
  • Radioisotopes e.g., tritium, 32 P, 33 P, 35 S, 14 C, 123 I, 124 I, 125 I, or
  • mass-tags including, but not limited to, stable isotopes (e.g., C, H, O, O, N, F, and
  • positron emitting isotopes e.g., C, F, N, I, and O
  • fluorescent labels are signal generating reporter groups which can be detected without further modifications.
  • Detectable moities may be analyzed by methods including, but not limited to fluorescence, positron emission tomography, SPECT medical imaging, chemiluminescence, electron-spin resonance, ultraviolet/visible absorbance spectroscopy, mass spectrometry, nuclear magnetic resonance, magnetic resonance, flow cytometry, autoradiography, scintillation counting, phosphoimaging, and electrochemical methods.
  • secondary label refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate for production of a detectable signal.
  • the secondary intermediate may include streptavidin-enzyme conjugates.
  • antigen labels secondary intermediates may include antibody-enzyme conjugates.
  • fluorescent label refers to moieties that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength.
  • fluorescent labels include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 493/503, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665), Carboxyr
  • Carboxytetramethylrhodamine (TAMRA), Texas Red, Texas Red-X, 5(6)-Carboxyfluorescein, 2,7-Dichlorofluorescein, N,N-Bis(2,4,6-trimethylphenyl)-3,4:9,10-perylenebis(dicarboximide, HPTS, Ethyl Eosin, DY-490XL MegaStokes, DY-485XL MegaStokes, Adirondack Green 520, ATTO 465, ATTO 488, ATTO 495, YOYO-l,5-FAM, BCECF, dichlorofluorescein, rhodamine 110, rhodamine 123, YO-PRO-1, SYTOX Green, Sodium Green, SYBR Green I, Alexa Fluor 500, FITC, Fluo-3, Fluo-4, fluoro-emerald, YoYo-1 ssDNA, YoYo-1 dsDNA, YoYo
  • mass-tag refers to any moiety that is capable of being uniquely detected by virtue of its mass using mass spectrometry (MS) detection techniques.
  • mass-tags include electrophore release tags such as N-[3-[4'-[(p- Methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]isonipecotic Acid, 4 ' -[2,3 ,5 ,6- Tetrafluoro-4-(pentafluorophenoxyl)]methyl acetophenone, and their derivatives.
  • mass-tags include, but are not limited to, nucleotides, dideoxynucleotides, oligonucleotides of varying length and base composition, oligopeptides, oligosaccharides, and other synthetic polymers of varying length and monomer composition.
  • nucleotides dideoxynucleotides
  • oligonucleotides of varying length and base composition oligopeptides, oligosaccharides
  • other synthetic polymers of varying length and monomer composition.
  • Stable isotopes e.g., C, H, O, O, and 15 N
  • Stable isotopes e.g., C, H, O, O, and 15 N
  • chemiluminescent group refers to a group which emits light as a result of a chemical reaction without the addition of heat.
  • luminol 5-amino-2,3-dihydro-l,4-phthalazinedione
  • oxidants like hydrogen peroxide (H 2 0 2 ) in the presence of a base and a metal catalyst to produce an excited state product (3- aminophthalate, 3-APA).
  • chromophore refers to a molecule which absorbs light of visible wavelengths, UV wavelengths or IR wavelengths.
  • die refers to a soluble, coloring substance which contains a chromophore.
  • electrostatic dense group refers to a group which scatters electrons when irradiated with an electron beam.
  • groups include, but are not limited to, ammonium molybdate, bismuth subnitrate, cadmium iodide, carbohydrazide, ferric chloride hexahydrate, hexamethylene tetramine, indium trichloride anhydrous, lanthanum nitrate, lead acetate trihydrate, lead citrate trihydrate, lead nitrate, periodic acid, phosphomolybdic acid, phosphotungstic acid, potassium ferricyanide, potassium ferrocyanide, ruthenium red, silver nitrate, silver proteinate (Ag Assay: 8.0-8.5%) "Strong", silver tetraphenylporphin (S-TPPS), sodium chloroaurate, sodium tungstate, thallium nitrate, thiosemicarbazide (TSC), ur
  • FRET fluorescence resonance energy transfer
  • molecular incorporating a heavy atom refers to a group which incorporates an ion of atom which is usually heavier than carbon.
  • ions or atoms include, but are not limited to, silicon, tungsten, gold, lead, and uranium.
  • photoaffinity label refers to a label with a group, which, upon exposure to light, forms a linkage with a molecule for which the label has an affinity.
  • photocaged moiety refers to a group which, upon illumination at certain wavelengths, covalently or non-covalently binds other ions or molecules.
  • photoisomerizable moiety refers to a group wherein upon illumination with light changes from one isomeric form to another.
  • radioactive moiety refers to a group whose nuclei spontaneously give off nuclear radiation, such as alpha, beta, or gamma particles; wherein, alpha particles are helium nuclei, beta particles are electrons, and gamma particles are high energy photons.
  • spin label refers to molecules which contain an atom or a group of atoms exhibiting an unpaired electron spin (i.e. a stable paramagnetic group) that in some embodiments are detected by electron spin resonance spectroscopy and in other embodiments are attached to another molecule.
  • spin-label molecules include, but are not limited to, nitryl radicals and nitroxides, and in some embodiments are single spin-labels or double spin-labels.
  • quantum dots refers to colloidal semiconductor nanocrystals that in some embodiments are detected in the near-infrared and have extremely high quantum yields (i.e., very bright upon modest illumination).
  • a detectable moiety may be attached to a provided compound via a suitable substituent.
  • suitable substituent refers to a moiety that is capable of covalent attachment to a detectable moiety.
  • moieties are well known to one of ordinary skill in the art and include groups containing, e.g., a carboxylate moiety, an amino moiety, a thiol moiety, or a hydroxyl moiety, to name but a few. It will be appreciated that such moieties may be directly attached to a provided compound or via a tethering moiety, such as a bivalent saturated or unsaturated hydrocarbon chain.
  • detectable moieties are attached to a provided compound via click chemistry.
  • such moieties are attached via a 1,3-cycloaddition of an azide with an alkyne, optionally in the presence of a copper catalyst.
  • Methods of using click chemistry are known in the art and include those described by Rostovtsev et al , Angew. Chem. Int. Ed. 2002, 41, 2596-99 and Sun et al, Bioconjugate Chem., 2006, 17, 52-57.
  • a click ready inhibitor moiety is provided and reacted with a click ready -T p -R p moiety.
  • click ready refers to a moiety containing an azide or alkyne for use in a click chemistry reaction.
  • the click ready inhibitor moiety comprises an azide.
  • the click ready -T p -R p moiety comprises a strained cyclooctyne for use in a copper-free click chemistry reaction (for example, using methods described in Baskin et al, Proc. Natl. Acad. Sci. USA 2007, 104, 16793-16797).
  • the click ready inhibitor moiety is of one of the following formulae:
  • Ring A, Ring B, Ring C, Ring D, T 1 , and T 2 are as defined above with respect to Formula I and described herein, X T is -0-, -NH-, or -NMe-, and each occurrence of f is independently 1, 2, or 3.
  • the click ready -T p -R p moiety is of formula:
  • the detectable moiety, R p is selected from a label, a dye, a photocrosslinker, a cytotoxic compound, a drug, an affinity label, a photoaffinity label, a reactive compound, an antibody or antibody fragment, a biomaterial, a nanoparticle, a spin label, a fluorophore, a metal-containing moiety, a radioactive moiety, quantum dot(s), a novel functional group, a group that covalently or noncovalently interacts with other molecules, a photocaged moiety, an actinic radiation excitable moiety, a ligand, a photoisomerizable moiety, biotin, a biotin analog (e.g., biotin sulfoxide), a moiety incorporating a heavy atom, a chemically cleavable group, a photocleavable group, a redox-active agent, an isotopically labeled moiety, a bio
  • R p is biotin or an analog thereof. In certain embodiments, R p is biotin. In certain other embodiments, R p is biotin sulfoxide.
  • R p is a fluorophore.
  • the fluorophore is selected from Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 493/503, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665), Carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Cascade Blue, Cascade Yellow, Coumarin
  • a provided probe compound comprises a tethering moiety, -T p -, that attaches the irreversible inhibitor to the detectable moiety.
  • tether or “tethering moiety” refers to any bivalent chemical spacer including, but not limited to, a covalent bond, a polymer, a water soluble polymer, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkylalkenylalkyl, an optionally substituted amide moiety, an ether moiety, an ketone moiety, an ester moiety, an optionally substituted carbamate moiety, an
  • the tethering moiety, -T p - is selected from a covalent bond, a polymer, a water soluble polymer, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkylalkenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkylalkenylalkyl.
  • the tethering moiety is an optionally substituted heterocycle.
  • the heterocycle is selected from aziridine, oxirane, episulfide, azetidine, oxetane, pyrroline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, pyrazole, pyrrole, imidazole, triazole, tetrazole, oxazole, isoxazole, oxirene, thiazole, isothiazole, dithiolane, furan, thiophene, piperidine, tetrahydropyran, thiane, pyridine, pyran, thiapyrane, pyridazine, pyrimidine, pyrazine, piperazine, oxazine, thiazine, dithiane, and dioxane.
  • the heterocycle is piperazine.
  • the tethering moiety is optionally substituted.
  • the tethering moiety is optionally substituted.
  • the tethering moiety provides sufficient spatial separation between the detectable moiety and the kinase inhibitor moiety. In further embodiments, the tethering moiety is stable. In yet a further embodiment, the tethering moiety does not substantially affect the response of the detectable moiety. In other embodiments, the tethering moiety provides chemical stability to the probe compound. In further embodiments, the tethering moiety provides sufficient solubility to the probe compound.
  • a tethering moiety, -T p - such as a water soluble polymer is coupled at one end to a provided irreversible inhibitor and to a detectable moiety, R p , at the other end.
  • a water soluble polymer is coupled via a functional group or substituent of the provided irreversible inhibitor.
  • a water soluble polymer is coupled via a functional group or substituent of the reporter moiety.
  • examples of hydrophilic polymers for use in tethering moiety -T p -, include, but are not limited to: polyalkyl ethers and alkoxy-capped analogs thereof (e.g., polyoxyethylene glycol, polyoxyethylene/propylene glycol, and methoxy or ethoxy-capped analogs thereof, polyoxyethylene glycol, the latter is also known as polyethylene glycol or PEG); polyvinylpyrrolidones; polyvinylalkyl ethers; polyoxazolines, polyalkyl oxazolines and polyhydroxyalkyl oxazolines; polyacrylamides, polyalkyl acrylamides, and polyhydroxyalkyl acrylamides (e.g., polyhydroxypropylmethacrylamide and derivatives thereof); polyhydroxyalkyl acrylates; polysialic acids and analogs thereof, hydrophilic peptide sequences; polysaccharides and their derivatives, including dextran and dex
  • a water soluble polymer is any structural form including but not limited to linear, forked or branched.
  • multifunctional polymer derivatives include, but are not limited to, linear polymers having two termini, each terminus being bonded to a functional group which is the same or different.
  • a water polymer comprises a poly(ethylene glycol) moiety.
  • the molecular weight of the polymer is of a wide range, including but not limited to, between about 100 Da and about 100,000 Da or more.
  • the molecular weight of the polymer is between about 100 Da and about 100,000 Da, including but not limited to, about 100,000 Da, about 95,000 Da, about 90,000 Da, about 85,000 Da, about 80,000 Da, about 75,000 Da, about 70,000 Da, about 65,000 Da, about 60,000 Da, about 55,000 Da, about 50,000 Da, about 45,000 Da, about 40,000 Da, about 35,000 Da, 30,000 Da, about 25,000 Da, about 20,000 Da, about 15,000 Da, about 10,000 Da, about 9,000 Da, about 8,000 Da, about 7,000 Da, about 6,000 Da, about 5,000 Da, about 4,000 Da, about 3,000 Da, about 2,000 Da, about 1 ,000 Da, about 900 Da, about 800 Da, about 700 Da, about 600 Da, about 500 Da, about 400 Da, about 300 Da, about 200 Da, and about 100 Da.
  • the molecular weight of the polymer is between about 100 Da and 50,000 Da. In some embodiments, the molecular weight of the polymer is between about 100 Da and 40,000 Da. In some embodiments, the molecular weight of the polymer is between about 1 ,000 Da and 40,000 Da. In some embodiments, the molecular weight of the polymer is between about 5,000 Da and 40,000 Da. In some embodiments, the molecular weight of the polymer is between about 10,000 Da and 40,000 Da. In some embodiments, the poly(ethylene glycol) molecule is a branched polymer.
  • the molecular weight of the branched chain PEG is between about 1 ,000 Da and about 100,000 Da, including but not limited to, about 100,000 Da, about 95,000 Da, about 90,000 Da, about 85,000 Da, about 80,000 Da, about 75,000 Da, about 70,000 Da, about 65,000 Da, about 60,000 Da, about 55,000 Da, about 50,000 Da, about 45,000 Da, about 40,000 Da, about 35,000 Da, about 30,000 Da, about 25,000 Da, about 20,000 Da, about 15,000 Da, about 10,000 Da, about 9,000 Da, about 8,000 Da, about 7,000 Da, about 6,000 Da, about 5,000 Da, about 4,000 Da, about 3,000 Da, about 2,000 Da, and about 1 ,000 Da.
  • the molecular weight of a branched chain PEG is between about 1 ,000 Da and about 50,000 Da. In some embodiments, the molecular weight of a branched chain PEG is between about 1 ,000 Da and about 40,000 Da. In some embodiments, the molecular weight of a branched chain PEG is between about 5,000 Da and about 40,000 Da. In some embodiments, the molecular weight of a branched chain PEG is between about 5,000 Da and about 20,000 Da.
  • the foregoing list for substantially water soluble backbones is by no means exhaustive and is merely illustrative, and in some embodiments, polymeric materials having the qualities described above are suitable for use in methods and compositions described herein.
  • the phrase "comprises a warhead group” means that the tethering moiety formed by -R 1 -T p - of formula II, Il-e, Il-f, II-f-i, II-f- ⁇ , or Il-f- iii is either substituted with a warhead group or has such a warhead group incorporated within the tethering moiety.
  • the tethering moiety formed by -R 1 -T p - may be substituted with an -L-Y warhead group, wherein such groups are as described herein.
  • the tethering moiety formed by -R 1 -! ⁇ - has the appropriate features of a warhead group incorporated within the tethering moiety.
  • the tethering moiety formed by -R 1 -T p - may include one or more units of unsaturation and optional substituents and/or heteroatoms which, in combination, result in a moiety that is capable of covalently modifying a kinase in accordance with the present invention.
  • Such -R 1 -!*- tethering moieties are depicted below.
  • a methylene unit of an -R 1 -T p - tethering moiety is replaced by a bivalent -L-Y'- moiety to provide a compound of formula II', Il'-e, ⁇ '-f, ⁇ - ⁇ - ⁇ , ⁇ -f-M, or Il'-f- iii:
  • each variable is as defined above for formulae I, I-e, I-f, l-f-i, l-f-ii, and l-f-iii,
  • Y' is a bivalent version of the Y group defined above and described in classes and subclasses herein.
  • a methylene unit of an -R 1 -T- tethering moiety is replaced by an -L(Y)- moiety to provide a compound of formula II", II"-e, II"-f, ll"-f-i, ll"-f-ii, or ll"-f-iii:
  • each variable is as defined above for formulae I, I-e, I-f, l-f-i, l-f-ii, and l-f-iii,
  • a tethering moiety is substituted with an L-Y moiety to provide a compound of formula II'", II"'-e, II"'-f, II'"-f-i, ll"'-f-ii, or W'-f-iu
  • each variable is as defined above for formulae I, I-e, I-f, l-f-i, l-f-ii, and l-f-iii,
  • the tethering moiety, -T p - has one of the following structures:
  • the tethering moiety, -T p - has the following structure:
  • the tethering moiety, -T p - has the following structure:
  • the tethering moiety, -T p - has the following structure:
  • the tethering moiety, -T p - has the following structure: [00334] :
  • -T p -R p is of the following structure:
  • -T p -R p is of the following structure:
  • -T p -R p is of the following structure:
  • a probe compound of formula II, Il-e, Il-f, II-f-i, II-f- ⁇ , or II- f-iii is derived from any compound of Table 3.
  • the present invention provides a method for determining occupancy of a kinase by a provided irreversible inhibitor (i.e., a compound of formula I, I-a, I- b, I-c, I-d, I-d-i, 1-d-i-a, I-e, I-e-i, 1-e-i-a, 1-e-i-b, I-f, l-f-i, l-f-ii, l-f-iii, l-f-i-a, l-f-ii-a, or I-f- iii-a) in a patient, comprising providing one or more tissues, cell types, or a lysate thereof, obtained from a patient administered at least one dose of a compound of said irreversible inhibitor, contacting said tissue, cell type or lysate thereof with a probe compound (e.g., a compound of formula II, Il-e, Il-f, II-f-i, II
  • the method further comprises the step of adjusting the dose of the compound of formula I, I-a, I-b, I-c, I-d, I-d-i, 1-d-i-a, I-e, I-e-/, 1-e-i-a, 1-e-i-b, I-f, l-f-i, l-f-ii, l-f-i-a, l-f-ii-a, or 1-f-iii-a to increase occupancy of the kinase.
  • the method further comprises the step of adjusting the dose of the compound of formula I, I-a, I-b, I-c, I-d, I-d-/, 1-d-i-a, I-e, I-e-/, 1-e-i-a, 1-e-i-b, I-f, l-f-i, l-f-ii, l-f-i-a, l-f-ii-a, or 1-f-iii-a to decrease occupancy of the kinase.
  • occupancy refers to the extent to which a kinase is modified by a provided covalent inhibitor compound.
  • a kinase is modified by a provided covalent inhibitor compound.
  • One of ordinary skill in the art would appreciate that it is desirable to administer the lowest dose possible to achieve the desired efficacious occupancy of the kinase.
  • the kinase to be modified is PI3K. In certain embodiments, the kinase to be modified is PI3K-a. In certain embodiments, the kinase to be modified is PI3K- ⁇ . In some embodiments, the kinase to be modified is PBK- ⁇ or PI3K-5. In other embodiments, the kinase to be modified is mTOR, DNA-PK, ATM kinase, or PI4KA.
  • the probe compound comprises the irreversible inhibitor for which occupancy is being determined.
  • the present invention provides a method for assessing the efficacy of a provided irreversible inhibitor in a mammal, comprising administering a provided irreversible inhibitor to the mammal, administering a provided probe compound to tissues or cells isolated from the mammal, or a lysate thereof, measuring the activity of the detectable moiety of the probe compound, and comparing the activity of the detectable moiety to a standard.
  • the present invention provides a method for assessing the pharmacodynamics of a provided irreversible inhibitor in a mammal, comprising administering a provided irreversible inhibitor to the mammal, administering a probe compound presented herein to one or more cell types, or a lysate thereof, isolated from the mammal, and measuring the activity of the detectable moiety of the probe compound at different time points following the administration of the inhibitor.
  • the present invention provides a method for in vitro labeling of a protein kinase comprising contacting said protein kinase with a probe compound described herein.
  • the contacting step comprises incubating the protein kinase with a probe compound presented herein.
  • the present invention provides a method for in vitro labeling of a protein kinase comprising contacting one or more cells or tissues, or a lysate thereof, expressing the protein kinase with a probe compound described herein.
  • the present invention provides a method for detecting a labeled protein kinase comprising separating proteins, the proteins comprising a protein kinase labeled by probe compound described herein, by electrophoresis and detecting the probe compound by fluorescence.
  • the present invention provides a method for assessing the pharmacodynamics of a provided irreversible inhibitor in vitro, comprising incubating the provided irreversible inhibitor with the target protein kinase, adding the probe compound presented herein to the target protein kinase, and determining the amount of target modified by the probe compound.
  • the probe compound is detected by binding to avidin, streptavidin, neutravidin, or captavidin.
  • the probe is detected by Western blot. In other embodiments, the probe is detected by ELISA. In certain embodiments, the probe is detected by flow cytometry.
  • the present invention provides a method for probing the kinome with irreversible inhibitors comprising incubating one or more cell types, or a lysate thereof, with a biotinylated probe compound to generate proteins modified with a biotin moiety, digesting the proteins, capturing with avidin or an analog thereof, and performing multidimensional LC-MS-MS to identify protein kinases modified by the probe compound and the adduction sites of said kinases.
  • the present invention provides a method for measuring protein synthesis in cells comprising incubating cells with an irreversible inhibitor of the target protein, forming lysates of the cells at specific time points, and incubating said cell lysates with an inventive probe compound to measure the appearance of free protein over an extended period of time.
  • the present invention provides a method for determining a dosing schedule in a mammal for maximizing occupancy of a target protein kinase comprising assaying a one or more cell types, or a lysate thereof, isolated from the mammal, (derived from, e.g., splenocytes, peripheral B cells, whole blood, lymph nodes, intestinal tissue, or other tissues) from a mammal administered a provided irreversible inhibitor of formula I, I-a, I-b, I-c, I-d, I-d- i, I-d-i-fl, I-e, I-e-i, I-e-i-a, I-e-i-b, I-f, l-f-i, I-f- ⁇ , l-f-iii, l-f-i- , l-f-ii- , or l-i-ii-a, wherein the assaying step comprises contacting said one
  • Step la 4-(6-chloro-4-iodopyridin-2-yl)morpholine (Intermediate la)
  • Step lb tert-butyl 4-(4-(2-chloro-6-morpholinopyridin-4-yl)phenyl)piperazine- 1-carboxylate (Intermediate lb)
  • Step lc tert-butyl 4-(4-(2-(2-aminopyrimidin-5-yl)-6-morpholinopyridin-4- yl)phenyl)piperazine-l-carboxylate (Intermediate lc)
  • Step 2a N-(4-((2-chloro-6-morpholinopyridin-4-yl)ethynyl)phenyl)-6-methyl- 4-oxohept-5-enamide (Intermediate 2a)
  • Step 2b N-(4-((2-(2-aminopyrimidin-5-yl)-6-morpholinopyridin-4- yl)ethynyl)phenyl)-6-methyl-4-oxohept-5-enamide (1-2).
  • step 4a When 5-nitro-2-(piperazin-l-yl)benzo[d]thiazole in place of 4-N-Boc-piperizane was used in step 4a, the compounds in the following table were prepared after nitro-reduction and HATU coupling.
  • HTRF Homogeneous Time Resolved Fluorescence
  • the protocol below describes an end-point, competition-binding HTRF assay used to measure inherent potency of test compounds against active PBKa (pi 10 ⁇ / ⁇ 85 ⁇ ), ⁇ (pi 10 ⁇ / ⁇ 85 ⁇ ), and ⁇ ( ⁇ 120 ⁇ ) enzymes.
  • the mechanics of the assay platform are best described by the vendor (Millipore, Billerica, MA) on their website at the following URL: www.millipore.com/coa/techl/74jt4z.
  • Stop solution (Stop A, #33-007 and Stop B, #33-009; 3 : 1 ratio) and Detection Mix (from DMC, #33-015 with DMA, #33-011 and DMB, #33-013; 18: 1 :1 ratio) were prepared as recommended by the manufacturer about 2 hrs prior to use.
  • IX reaction buffer (from 4X buffer stock# 33-003), 1.4X stocks of ⁇ , ⁇ , and ⁇ 3 ⁇ enzymes from BPS Bioscience (San Diego, CA) or Millipore (Billerica, MA) with di-Cg-PIP 2 lipid substrate (#33- 005), and a 4X ATP solution (#A7699 Sigma /Aldrich; St.
  • Table 6 shows the activity of selected compounds of this invention in the PBKa HTPvF assays.
  • Compounds having an activity designated as "A” provided an IC 50 ⁇ 10 nM; compounds having an activity designated as “B” provided an IC 50 of 10-100 nM; compounds having an activity designated as “C” provided an IC 50 of 100-1000 nM; and compounds having an activity designated as "D” provided an IC 50 of >1000 nM.
  • “-" indicates that the value was not determined.
  • HCT116 colon cancer cells are plated overnight and then aer incubated for 1 hour with varying concentrations of inhibitors (5, 2, 0.5, 0.1 and 0.02 ⁇ ). Cells are then washed with PBS, lysed and the protein lysates are then recovered and analyzed by Western blot.
  • inhibitors 5, 2, 0.5, 0.1 and 0.02 ⁇
  • SKOV3 cells are plated in SKOV3 Growth Media (DMEM supplemented with 10% FBS and pen/strep) at a density of 4 x 10 5 cells per well of 12 well plates. Twenty four hours later the media is removed and replaced with 1 ml media containing test compound and 0.1% DMSO and cells are returned to the incubator for 1 hr. At the end of the hour, the media is removed and the cells are washed with PBS, then lysed and scraped into 30ul of Cell Extraction Buffer (Biosource, Camarillo, CA) plus Complete Protease Inhibitor and PhosStop Phosphatase Inhibitor (Roche, Indianapolis, IN).
  • Cell debris is spun down at 13,000 x g for 1 minute and the supernatant is taken as the cell lysate. Protein concentration of the lysate is determined by BCA Assay (Pierce Biotechnology, Rockford, IL) and 50 ug of protein is loaded per well onto a NuPAGE No vex 4- 12% Bis-Tris gel (Invitrogen, Carlsbad, CA) then is transferred to Immobilon PVDF-FL (Millipore, Billerica, MA).
  • the blots are washed 3 times 5 minutes in PBS + 0.2% Tween-20 then are incubated for 1 hr at room temperature with fluorescently labeled secondary antibodies (Li-Cor) diluted 1 : 10000 in PBS/Odyssey Buffer (1 : 1) + 0.1% Tween-20.
  • the formaldehyde is removed and cells are washed 5 times for 5 minutes with 100 ul of Permeabilization Buffer (PBS + 0.1% Triton X-100) at room temperature with gentle shaking. The last wash is removed and is replaced with 150 ul of Odyssey Blocking Buffer (Li-Cor, Lincoln, NE) and is incubated for 90 minutes at room temperature with gentle shaking.
  • Permeabilization Buffer PBS + 0.1% Triton X-100
  • Blocking Buffer is then replaced with 50 ul of primary antibody mix (rabbit anti- Phospho-Akt(Ser473) at 1 : 100 (Cell Signaling Technology, Boston, MA) and mouse anti-tubulin at 1 :5000 (Sigma Aldrich, St.Louis, MO), is diluted in Odyssey Blocking Buffer) and is incubated overnight at room temperature with gentle shaking.
  • primary antibody mix rabbit anti- Phospho-Akt(Ser473) at 1 : 100 (Cell Signaling Technology, Boston, MA) and mouse anti-tubulin at 1 :5000 (Sigma Aldrich, St.Louis, MO)
  • the plates are scanned on an Odyssey machine (Li-Cor) with a 3mm focus offset at an intensity of 8 in both channels and the data is analyzed using the Odyssey software.
  • Li-Cor Li-Cor
  • SKOV3 cells are plated in SKOV3 Growth Media (DMEM supplemented with 10% FBS and pen/strep) at a density of 2.5 x 10 4 cells per well of Costar #3603 black 96 well clear flat bottom plates. Plates are set up in quadruplicate with one plate each for the 0, 1, 6 and 24 hour time points.
  • the media is removed and is replaced with 100 ul media containing a provided compound or DMSO as a control and cells are returned to the incubator for 1 hr.
  • the media is removed and the cells are washed 2 times with PBS.
  • the PBS is removed from three of the plates, replaced with 100 ul of Growth Media and the plates are returned to the incubator.
  • the fourth plate is taken as the 0 hour time point and is developed as described for In-Cell Western Dose Response.
  • Other compounds that modify ⁇ 3 ⁇ >50% after 1 hr include 1-1, 1-2, 1-12, 1-17, and I- 19.
  • HCT116 Proliferation Assay 3000 cells per well are plated in Growth Media (DMEM, 10% FBS, 1% 1-glutamine, 1% penicillin/streptomycin) in 96 well plates. The following day, compounds are added to duplicate wells at concentrations of 10 uM and 3 -fold dilutions down to 40 nM. The plates are returned to the incubator for 72 hours and then the assays are developed using Cell Titer Glo (Promega, Madison, WI) according to manufacturer's instructions.
  • DMEM 10% FBS, 1% 1-glutamine, 1% penicillin/streptomycin
  • SK-OV-3 proliferation Assay 5000 cells per well are plated in Growth Media (DMEM, 10% FBS, 1% 1-glutamine, 1% penicillin/streptomycin)in 96 well plates. The following day, compounds are added to duplicate wells at concentrations of 10 uM and 3 -fold dilutions down to 40 nM. The plates are returned to the incubator for 72 hours and then the assays are developed using Cell Titer Glo (Promega, Madison, WI) according to manufacturer's instructions.
  • DMEM 10% FBS, 1% 1-glutamine, 1% penicillin/streptomycin
  • the cells are incubated for 96 hours and are then developed with Cell Titer Glo.
  • the cell numbers at the end of the assay are determined using the standard curve generated at the start of the assay. Growth inhibition is calculated using the following formulas and GI50s are determined by plotting the % growth inhibition vs. Log compound concentration in GraphPad.
  • T 0 Cell Number at start of assay (5000)
  • SKOV-3 cells are treated with a provided compound.
  • 150 ug of protein sample is added to a 0.2 ml tube and the volume is brought up to 100 ul with IP Buffer from the Protein A/G Plate IP Kit (Pierce Biotechnology, Rockford, IL).
  • a provided probe compound is added at a concentration of 1 uM and the tube is incubated at room temperature with rocking for 1 hr.
  • Protein A/G coated wells from the Protein A/G Plate IP Kit are washed 3 X with 200 ul of IP Buffer.
  • the wells are then coated with 4 ul rabbit anti-pl 10 alpha antibody #4249 (Cell Signaling Technology, Danvers, MA) plus 36 ul of IP Buffer per well.
  • the wells are washed 5 X with 200 ul of IP Buffer and the protein samples, preincubated with a provided probe compound, are added to the wells.
  • the wells are incubated overnight at 4 °C with shaking.
  • the blot is then incubated overnight at 4 °C with rabbit anti-pl 10 alpha antibody (Epitomics, Burlingame, CA) diluted 1 :2500 in PBS/Odyssey Buffer (1 : 1) + 0.1% Tween-20.
  • the blot is washed 3 times 5 minutes in PBS + 0.2% Tween-20 then incubated for 1 hr at room temperature with streptavidin-AlexaFluor-680 (Invitrogen) diluted 1 : 1000 and fluorescently labeled goat anti-rabbit-IRDye800 (Li-Cor) diluted 1 : 10000 in PBS/Odyssey Buffer (1 : 1) + 0.1% Tween-20.
  • the blots are washed 2 times for 5 minutes in PBS + 0.2% Tween-20, once in distilled water, then are scanned on an Odyssey machine (Li-Cor, Lincoln, NE). Band intensity is determined using the Odyssey software and streptavidin (probe) signal is normalized to total pi 10 alpha signal within samples, then is expressed as a percentage of the untreated signal.

Abstract

La présente invention concerne des composés, des compositions associées et des procédés d'utilisation associés.
PCT/US2012/028293 2011-03-09 2012-03-08 Inhibiteurs de pi3 kinase et leurs utilisations WO2012122383A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201280021536.0A CN103501610A (zh) 2011-03-09 2012-03-08 Pi3激酶抑制剂和其用途
CA2829558A CA2829558A1 (fr) 2011-03-09 2012-03-08 Inhibiteurs de pi3 kinase et leurs utilisations
JP2013557866A JP2014511395A (ja) 2011-03-09 2012-03-08 Ｐｉ３キナーゼインヒビターおよびその使用
AU2012225382A AU2012225382B2 (en) 2011-03-09 2012-03-08 PI3 kinase inhibitors and uses thereof
EP12755552.2A EP2683243A4 (fr) 2011-03-09 2012-03-08 Inhibiteurs de pi3 kinase et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451022P 2011-03-09 2011-03-09
US61/451,022 2011-03-09

Publications (2)

Publication Number Publication Date
WO2012122383A2 true WO2012122383A2 (fr) 2012-09-13
WO2012122383A3 WO2012122383A3 (fr) 2012-12-27

Family

ID=46798805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/028293 WO2012122383A2 (fr) 2011-03-09 2012-03-08 Inhibiteurs de pi3 kinase et leurs utilisations

Country Status (7)

Country Link
US (1) US20120258967A1 (fr)
EP (1) EP2683243A4 (fr)
JP (1) JP2014511395A (fr)
CN (1) CN103501610A (fr)
AU (1) AU2012225382B2 (fr)
CA (1) CA2829558A1 (fr)
WO (1) WO2012122383A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014177060A1 (fr) * 2013-05-01 2014-11-06 F.Hoffmann-La Roche Ag Composés bihétéroaryle et leurs utilisations
CN104140426A (zh) * 2013-05-07 2014-11-12 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN104651368A (zh) * 2013-11-15 2015-05-27 北京大学 一种核酸适配体bc15的核心序列及其类似物和应用
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US10406133B2 (en) 2013-03-14 2019-09-10 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2019238933A1 (fr) * 2018-06-15 2019-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de pi3kc2b pour la préservation de l'intégrité d'une barrière cellulaire de l'endothélium vasculaire
US11230548B2 (en) 2013-03-14 2022-01-25 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
CN115417789A (zh) * 2022-09-03 2022-12-02 郑州大学 一种治疗帕金森氏病的新化合物、其制备方法以及复方药物组合物和应用
WO2023154282A1 (fr) * 2022-02-08 2023-08-17 Theras, Inc. Composés ayant une structure t formée par au moins quatre cycles destinés à être utilisés dans le traitement du cancer et d'autres indications
US11766420B2 (en) 2015-04-30 2023-09-26 Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013251475B2 (en) 2012-04-26 2018-01-04 The General Hospital Corporation Agents and methods for treating and preventing seborrheic keratosis
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
MX2015011514A (es) * 2013-03-15 2016-08-11 Celgene Avilomics Res Inc Compuestos de heteroarilo y sus usos.
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
WO2014186663A2 (fr) * 2013-05-17 2014-11-20 The General Hospital Corporation Procédés de détection et de traitement de variantes de kératoses séborrhéiques
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2019199864A1 (fr) * 2018-04-10 2019-10-17 Neuropore Therapies, Inc. Dérivés d'aryle et d'hétéroaryle tri-substitués utilisés en tant que modulateurs de la pi3-kinase et des voies de l'autophagie
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004257289A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
CN1823057A (zh) * 2003-07-16 2006-08-23 神经能质公司 二芳基哌嗪基－吡啶类似物
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
EP1824839A2 (fr) * 2004-12-13 2007-08-29 Neurogen Corporation Analogues de biaryle substitues
JP5500990B2 (ja) * 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
CN101711241A (zh) * 2007-02-06 2010-05-19 诺瓦提斯公司 Pi3-激酶抑制剂和它们的使用方法
EP2211615A4 (fr) * 2007-10-22 2010-10-13 Glaxosmithkline Llc Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase
WO2009066084A1 (fr) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3
WO2009070524A1 (fr) * 2007-11-27 2009-06-04 Wyeth Composés de pyrrolo[3,2-d]pyrimidine et leur utilisation comme inhibiteurs de la pi3 kinase et de la mtor kinase
JP5520831B2 (ja) * 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
DE102009015255A1 (de) * 2009-04-01 2010-10-14 GM Global Technology Operations, Inc., Detroit Tankklappenmodul
CA2755554C (fr) * 2009-04-17 2013-09-24 Wyeth Llc Composes de pyrimidine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase et leurs procedes de synthese
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
AU2010292198A1 (en) * 2009-09-09 2012-04-05 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
WO2013033901A1 (fr) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2683243A4 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905298B2 (en) 2013-03-14 2024-02-20 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US11679092B2 (en) 2013-03-14 2023-06-20 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US11230548B2 (en) 2013-03-14 2022-01-25 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US11083703B2 (en) 2013-03-14 2021-08-10 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10596140B2 (en) 2013-03-14 2020-03-24 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10406133B2 (en) 2013-03-14 2019-09-10 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10028954B2 (en) 2013-04-30 2018-07-24 Genentech, Inc. Biheteroaryl compounds and uses thereof
US11129832B2 (en) 2013-05-01 2021-09-28 Genentech, Inc. Biheteroaryl compounds and uses thereof
JP2020079264A (ja) * 2013-05-01 2020-05-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ビヘテロアリール化合物及びその使用
EA029568B1 (ru) * 2013-05-01 2018-04-30 Ф.Хоффманн-Ля Рош Аг Бигетероарильные соединения и их применения
US10010549B2 (en) 2013-05-01 2018-07-03 Genentech, Inc. Biheteroaryl compounds and uses thereof
US9266862B2 (en) 2013-05-01 2016-02-23 Genentech, Inc. Biheteroaryl compounds and uses thereof
CN105431420B (zh) * 2013-05-01 2019-08-13 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
EA033084B1 (ru) * 2013-05-01 2019-08-30 Ф.Хоффманн-Ля Рош Аг Бигетероарильные соединения и их применения
WO2014177060A1 (fr) * 2013-05-01 2014-11-06 F.Hoffmann-La Roche Ag Composés bihétéroaryle et leurs utilisations
CN105431420A (zh) * 2013-05-01 2016-03-23 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
USRE47848E1 (en) 2013-05-01 2020-02-11 Genentech, Inc. Biheteroaryl compounds and uses thereof
JP2016518383A (ja) * 2013-05-01 2016-06-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ビヘテロアリール化合物及びその使用
JP2018035187A (ja) * 2013-05-01 2018-03-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ビヘテロアリール化合物及びその使用
EA038235B1 (ru) * 2013-05-01 2021-07-28 Ф.Хоффманн-Ля Рош Аг Бигетероарильные соединения и их применения
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN104140426A (zh) * 2013-05-07 2014-11-12 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN104651368A (zh) * 2013-11-15 2015-05-27 北京大学 一种核酸适配体bc15的核心序列及其类似物和应用
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US11766420B2 (en) 2015-04-30 2023-09-26 Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease
WO2019238933A1 (fr) * 2018-06-15 2019-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de pi3kc2b pour la préservation de l'intégrité d'une barrière cellulaire de l'endothélium vasculaire
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11944622B2 (en) 2018-10-05 2024-04-02 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
WO2023154282A1 (fr) * 2022-02-08 2023-08-17 Theras, Inc. Composés ayant une structure t formée par au moins quatre cycles destinés à être utilisés dans le traitement du cancer et d'autres indications
CN115417789A (zh) * 2022-09-03 2022-12-02 郑州大学 一种治疗帕金森氏病的新化合物、其制备方法以及复方药物组合物和应用
CN115417789B (zh) * 2022-09-03 2023-08-04 郑州大学 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用

Also Published As

Publication number Publication date
EP2683243A2 (fr) 2014-01-15
JP2014511395A (ja) 2014-05-15
EP2683243A4 (fr) 2014-12-03
CA2829558A1 (fr) 2012-09-13
AU2012225382B2 (en) 2016-10-27
US20120258967A1 (en) 2012-10-11
CN103501610A (zh) 2014-01-08
WO2012122383A3 (fr) 2012-12-27
AU2012225382A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
AU2012225382B2 (en) PI3 kinase inhibitors and uses thereof
TWI499592B (zh) Ｐｉ３激酶抑制劑及其用途
US11241473B2 (en) Bicyclic peptide ligands and uses thereof
CN110062759A (zh) 作为bet蛋白降解剂的稠合的1,4-氧氮杂*
EP3870597A1 (fr) Ligands peptidiques bicycliques et leurs utilisations
BRPI1015568B1 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
CN101678026A (zh) 作为磷脂酰肌醇-3-激酶抑制剂的3,6-二取代的-咪唑并[1,2-b]哒嗪和3,5-二取代的-吡唑并[1,5-a]嘧啶
CN101516885A (zh) 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
TW200819444A (en) Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
MXPA06005702A (es) Derivados de 1h-imidazoquinolina como inhibidores de quinasa de proteina.
TW201000468A (en) Quinoxaline-and quinoline-carboxamide derivatives
CN104902959A (zh) Irak抑制剂和其用途
US9339501B2 (en) 17a-hydroxylase/C17,20-lyase inhibitors
TW201107332A (en) 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12755552

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2829558

Country of ref document: CA

Ref document number: 2013557866

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012755552

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012755552

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012225382

Country of ref document: AU

Date of ref document: 20120308

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12755552

Country of ref document: EP

Kind code of ref document: A2